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ABSTRACT 
 
Most breast cancer patients undergo radiation diagnostics and are also 
treated with radiotherapy. In addition to being an important treatment modality, 
ionizing radiation (IR) is a potent tumour-causing agent that has been linked to 
breast cancer development. However, the exact molecular etiology of IR-
induced mammary gland carcinogenesis remains unknown.  
We set out to analyze the role of DNA methylation in mammary gland 
responses to low dose IR using a well-established rat model.  We also studied 
low dose IR effects on global gene expression and microRNAome. We found 
that exposure to low, mammography-like dose of IR led to a significant loss of 
global DNA methylation in rat mammary gland tissue. Furthermore, low dose IR 
significantly affected rat mammary gland transcriptome and microRNAome.  
The datasets generated within the scope of this thesis may be used to 
identify novel predictive biomarkers for assessment of the magnitude of IR 
effects on mammary gland tissue.  
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INTRODUCTION 
RADIATION EFFECTS - A HISTORIC PERSPECTIVE 
Radiation exposure to humans occurs to everyone on a daily basis; this 
form is known as cosmic radiation, which originates from outside of our solar 
system.  Humans are also exposed to other types of radiation such as specific 
isotopes of potassium, uranium, and thorium (that are naturally located within 
the earth).  One of the largest sources of radiation exposure to humans comes 
from man-made sources such as medical diagnostic tools, nuclear power, 
weapons of mass destruction, food sterilization, and safety measures such as x-
ray scanners located in airports. There is much debate over the risk associated 
with exposure to various doses of ionizing radiation.   
In 1991, the International Commission on Radiological Protection 
adopted a linear no-threshold (LNT) hypothesis as a fundamental basis for 
predicting the risk associated with exposure to ionizing radiation (Protection) 
1991).  The LNT phenomenon for humans basically means that not only is the 
risk directly proportional to the total dose, but that there is no threshold below 
which exposure does NOT pose a risk.  Because of this “no-threshold,” it can be 
postulated that multiple doses of any level can create some sort of risk, thus 
can be treated as additive.  Yet, based on observational data, and not the LNT 
hypothesis, it has previously been assumed that the risk associated with low 
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dose exposure is much less than that of higher dose exposures (Mitchel 2007).   
In the last 5-10 years this line of thought has come into serious question 
(Tubiana, Aurengo et al. 2006). Recent studies have provided compelling 
evidence that low energy x-rays (similar to those used for mammography breast 
screening) are 2 – 6 times more effective in causing mutational damage to 
breast tissue than higher energy x-rays (Frankenberg, Kelnhofer et al. 2002; 
Frankenberg, Kelnhofer et al. 2002; Heyes, Mill et al. 2009). 
Cells respond to ionizing radiation in a few different manners and may 
even undergo a form of an adaptive response.  Cellular adaptive response has 
been described as a mechanism by which cells protect themselves against the 
detrimental effects of subsequent harmful events (Mitchel 2007).  One form of 
cellular adaptive response has been termed the “bystander effect” (Mitchel, 
Jackson et al. 2004; Asur, Balasubramaniam et al. 2010; Asur, 
Balasubramaniam et al. 2010; Tsukimoto, Homma et al. 2010; Wright 2010).  
The bystander effect occurs when only some of an organisms cells receive a 
low dose of ionizing radiation and subsequently pass along the “protective 
message” to surrounding cells through chemical signalling. 
Therefore, some researchers feel that radiation  at low levels actually 
promotes such a  type of “protectiveness” for the cell or organism (Ahmed, Fan 
et al. 2008; Mishra, Ahmed et al. 2008; Tsai, Stuart et al. 2009), while their 
opponents hold to the linear no-threshold (LNT) limit theory.  
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Due to the compelling data obtained by researchers who are 
investigating the effects of low-dose ionizing radiation on various organisms’ 
systems, one may predict that the LNT limit theory is the better choice for 
assessing the actual risk with exposure to any dose level of IR, especially when 
it comes to human exposure.  Notwithstanding, it has been a very difficult to 
substantiate the LNT theory based on epidemiological studies.  Because cancer 
is the disease feared and associated the most with exposure to any level of IR, 
when scientists and statisticians try to associate low level IR exposure with 
cancer, many other factors must be considered because of their known (or 
suspected) contribution to the initiation and propagation of cancer (such as 
smoking, alcohol consumption, diet, occupation, age, sex, etc.) which adds a 
great deal of complexity to the situation. 
We have progressed a great deal with respect to our knowledge of 
ionizing radiation and it’s direct, indirect, short term, and/or long term effects 
that are induced in radiation-exposed living organisms and most importantly, 
humans.  For instance, in the early 1900’s, the “shoe-fitting fluoroscope,” 
designed by the Adrian X-ray Company, was used to assess how a shoe fit your 
foot before you bought it.  This practice went on for approximately 25 years, 
until doctors and researchers started to become more concerned with exposure 
to radiation (Lewis and Caplan 1950).  Due to accumulation of a substantial 
amount of data on radiation effects, today an idea like this would be considered 
ludicrous and would never be allowed to be put into public use. 
4 
 
Notwithstanding, a lot has to be learned about the molecular and cellular effects 
of radiation exposure in general and low dose radiation exposure in particular. 
RADIATION AND CANCER 
Ionizing radiation (IR) is an important diagnostic and treatment modality. 
Notwithstanding, it is a potent DNA damaging agent that can lead cause serious 
health effects including cancer (Little 1999). The first IR-induced cancer was 
reported in 1902 (Little 2000). Yet, IR still remains the key diagnostic and 
treatment tool for the majority of cancers (Pollack, Zagars et al. 2000; Roof, 
Fidias et al. 2003; Potter 2006; Erven and Van Limbergen 2007). However, 
while modern cancer IR-based diagnostics and IR therapy have led to 
increased patient survival rates, the risk of treatment-related deleterious effects, 
including secondary cancers, is becoming a growing problem (Boice, Harvey et 
al. 1992; Leone, Mele et al. 1999; Brenner, Curtis et al. 2000; Rund and Ben-
Yehuda 2004; Brenner, Hall et al. 2005; Hall 2006). 
Furthermore, data suggest that even relatively low doses of IR such as 
those being used in X-ray diagnostic procedures or Computer Tomography can 
underlie the development of IR-induced cancers (Preston-Martin, Thomas et al. 
1989; Brenner and Hall 2004). A large pool of knowledge about IR-induced 
effects stems from data of atomic bomb survivors and individuals that were 
exposed to radiation as a result of industrial accidents. The atomic bomb 
survivor studies show that IR exposures lead to significantly increased cancer 
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rates, especially leukemia (Folley, Borges et al. 1952), breast cancer 
(Watanabe, Shimosato et al. 1972; Wakabayashi, Kato et al. 1983; Carmichael, 
Sami et al. 2003), thyroid carcinoma (Watanabe, Shimosato et al. 1972; 
Wakabayashi, Kato et al. 1983), and lung and stomach cancers (Wakabayashi, 
Kato et al. 1983). The significantly elevated cancer rates were also reported in 
human populations exposed to IR from nuclear power accidents and at various 
nuclear test sites (Kossenko 1996; Shilnikova, Preston et al. 2003). 
Amongst the accidents, the Chernobyl disaster in April 1986 was the 
most devastating. It led to significant increases in the incidence of thyroid 
carcinomas (Bogdanova, Zurnadzhy et al. 2006; Likhtarov, Kovgan et al. 2006; 
Williams 2006) , leukaemia and lymphoma (Gluzman, Imamura et al. 2005; 
Balonov 2007), breast cancer (Pukkala, Kesminiene et al. 2006; Prysyazhnyuk, 
Gristchenko et al. 2007), bladder cancer (Morimura, Romanenko et al. 2004), 
and renal-cell carcinomas (Romanenko, Morimura et al. 2000; Baverstock and 
Williams 2006; Williams and Baverstock 2006). Elevated cancer rates were also 
documented as being reported in the population of the Semipalatinsk nuclear 
test site (Salomaa, Lindholm et al. 2002; Tanaka, Iida et al. 2006).  
Ionizing radiation influences a wide variety of processes in exposed 
cells. It can lead to changes in gene expression, disruption of mitochondrial 
processes, cell cycle arrest and apoptotic cell death (Amundson, Bittner et al. 
2003; Amundson and Fornace 2003; Criswell, Klokov et al. 2003; Fei and El-
Deiry 2003; Iliakis, Wang et al. 2003; Powell and Kachnic 2003; Jeggo and 
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Lobrich 2006; Rodemann, Dittmann et al. 2007; Valerie, Yacoub et al. 2007)    
Most importantly, IR is a powerful DNA damaging agent capable of inducing  
cross linking, nucleotide base damage and single and double strand breaks 
(Ward 1995; Little 2000; Huang, Fang et al. 2003). Accumulation of DNA 
damage caused by IR in conjunction with disrupted cellular regulation 
processes can lead to carcinogenesis (Little and Muirhead 2000; Barcellos-Hoff 
2005; Sowa, Arthurs et al. 2006). 
BREAST CANCER  -  INCIDENCE AND MOLECULAR AETIOLOGY 
Breast cancer is the most common type of malignancy in women 
(Parkin 2001; Parkin, Bray et al. 2005) with worldwide incidence continuing to 
rise (Ellsworth, Ellsworth et al. 2004). Breast cancer has become the second 
leading cause of cancer-related deaths among North American women and the 
leading cause of death among women aged 35 to 55 years (Widschwendter and 
Jones 2002; Schairer, Mink et al. 2004). According to the Canadian Cancer 
Society, approximately 22, 700 women will be diagnosed with breast cancer in 
one year and 5400 will die from it.  That is to say that on average, 437 
Canadian women will be diagnosed with breast cancer every week and 104 will 
die from breast cancer every week. 
In order to understand how breast cancer starts and propagates (with 
the possibility leading to new methods of treatment and possible cure) one must 
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first understand the parts of the breast and their function and/or purpose.  The 
human breast is made up of glands, ducts and fatty tissue. 
Breast cancer progresses similarly to the other cancer types, and the 
stages of breast carcinogenesis include initiation, propagation and later- 
metastasis.  There are many types of breast cancer including phyllodes tumors, 
angiosarcomas (both beginning in the connective tissue of the breast) 
(Bjurstam, Bjorneld et al. 1997; Dalberg, Mattsson et al. 1997; Reis-Filho, 
Simpson et al. 2005; Li, Daling et al. 2006), ductal carcinoma and lobular 
carcinoma (Daling, Malone et al. 2002; Li, Malone et al. 2003; Li, Daling et al. 
2006), which are primarily defined by the location of the tumor within the 
mammary gland.  Not only are breast cancers defined by where they start, but 
also whether or not they are invasive (i.e. spreading outside of the membrane 
that lines the duct or lobule, thus associated with the stage/level of cancer) or 
non-invasive (meaning they remain within the tissue of origin). 
When a patient is diagnosed with breast cancer, the method(s) of 
treatment utilized by the physician will be based on a number of criteria, 
including the stage and grade of the tumor, the hormone receptor status, HER2 
receptor status, the type of breast cancer, age and overall health of the patient, 
menopausal status and the personal preference and/or situation of the patient.  
Breast cancer treatments can include one or a combination of the following: 
surgery, radiation therapy, chemotherapy, hormonal therapy and biological 
therapy (enhancing the individuals’ own immune system to aid in the fighting of 
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the cancer) (Li, Daling et al. 2006). The sequential accumulation of various 
genetic changes in the genesis of breast cancer has been studied (Shackney 
and Silverman 2003; Ellsworth, Ellsworth et al. 2004; Simpson, Reis-Filho et al. 
2005), whereas the contribution of epigenetic alterations to the early molecular 
aetiology of breast cancer must still be analyzed. 
The cellular and biological mechanisms that are implicated in the 
predisposition, initiation and progression of human breast cancer are still poorly 
understood, however it is an area of great interest.  If we can deepen our 
understanding of these mechanisms, it can provide a great deal of aid in the 
prevention and treatment of breast cancer. 
RADIATION EXPOSURE AND BREAST CANCER  
Only 5% of breast cancer cases are due to abnormal genetic function 
(Ronckers, Erdmann et al. 2005).  Factors contributing to the remaining 95% of 
breast cancer cases remain unclear; however, the role of environmental 
mutagens in breast cancer etiology has recently received a lot of attention  
(Ronckers, Erdmann et al. 2005).  Amongst these, ionizing radiation (IR) has 
been shown to strongly induce breast cancer in exposed individuals (Boice, 
Preston et al. 1991; Storm, Andersson et al. 1992; Mattsson, Ruden et al. 1993; 
Howe and McLaughlin 1996; Mattsson, Hall et al. 1997; Brenner, Sawant et al. 
2002; Land, Tokunaga et al. 2003; Constine, Tarbell et al. 2008).  Awareness of 
IR-induced breast cancer is derived from epidemiological studies of atomic 
bomb survivors and women exposed to diagnostic and therapeutic irradiation 
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(Boice, Preston et al. 1991; Storm, Andersson et al. 1992; Mattsson, Ruden et 
al. 1993; Howe and McLaughlin 1996; Land, Tokunaga et al. 2003).  IR-induced 
breast cancer in the medically-exposed population is a growing clinical problem 
(Ronckers, Erdmann et al. 2005).  Elevated breast cancer risks have been 
reported in patients with scoliosis and tuberculosis (Boice, Preston et al. 1991; 
Howe and McLaughlin 1996), women treated for benign breast disease and 
post-partum mastitis (Mattsson, Ruden et al. 1993; Land, Tokunaga et al. 2003; 
Ronckers, Erdmann et al. 2005) and in cancer survivors, all of whom have 
received radiation therapy (Storm, Andersson et al. 1992; Ronckers, Erdmann 
et al. 2005). Average IR-exposure doses linked to the development of breast 
cancer range between 0.2 and 20 Gy (Ronckers, Erdmann et al. 2005).  IR-
exposure is especially dangerous in young women.  Women irradiated for 
Hodgkin’s disease when <30 years of age have a much higher risk of breast 
cancer (Constine, Tarbell et al. 2008). 
 
There has been much debate about benefits and risks of diagnostic 
mammography in the detection of breast cancer (Brenner, Sawant et al. 2002; 
Berrington de Gonzalez and Reeves 2005; Nekolla, Griebel et al. 2008). 
Specifically, risks of mammography-related IR-exposure in conjunction with 
risks of IR-induced carcinogenesis (Brenner, Sawant et al. 2002; Berrington de 
Gonzalez and Reeves 2005; Constine, Tarbell et al. 2008; Nekolla, Griebel et al. 
2008) have been questioned.  Glandular doses from mammography are low, 
typically around 3 mGy of 26-30kVp X-rays (Kruger and Schueler 2001; 
10 
 
Brenner, Sawant et al. 2002); however the main concern is that these low 
energy rays are more hazardous, per unit dose, than high-energy X- or γ-rays 
(Brenner, Sawant et al. 2002).  Low-energy X-rays exhibited a higher 
oncotransformation potential than 200kVp X-rays, suggesting that low-energy X-
rays used in mammography are considerably more biologically active than 
previously thought (Frankenberg, Kelnhofer et al. 2002; Frankenberg, Kelnhofer 
et al. 2002).  This finding is consistent with the data on chromosome aberration 
induction by low energy X-rays (Brenner and Amols 1989).  
 
In vitro studies (Shellabarger 1976; van Bekkum and Broerse 1991; 
Russo and Russo 1996; Ronckers, Erdmann et al. 2005) have also shown that 
IR can alter tissue function by promoting neoplastic transformation of normal 
breast cells (Calaf and Hei 2000; Calaf and Hei 2001; Calaf, Alvarado et al. 
2005), but specific mechanisms have not been determined as of this point in 
time.  Molecular mechanisms contributing to the etiology of IR-induced breast 
carcinogenesis consist of prominent genetic and epigenetic changes and have 
been the subject of extensive research in recent years.  
 
The sequential accumulation of various genetic changes in the genesis 
of breast cancer has been studied, whereas the contribution of epigenetic 
alterations to the early molecular etiology of breast cancer still must be 
analyzed. 
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EPIGENETICS AND CANCER 
The term “epigenetics” has become a very common term used in the 
various fields of molecular biology.  Basically, it has been defined as changes in 
gene expression based on heritable factors that do not involve changes to the 
DNA sequence.  Epigenetic processes encompass meiotically heritable and 
mitotically stable alterations in gene expression that include DNA methylation, 
histone modification, and RNA-associated silencing (Jaenisch and Bird 2003).  
DNA Methylation 
Mammalian DNA methylation has been described as a covalent 
addition of a methyl group at the 5-carbon position of the cytosine residues 
found within cytosine-guanine dinucleotides (CpG).  Methylation  plays a key 
part in controlling gene expression, genetic imprinting, and tissue- or temporal- 
specific gene expression (Gopalakrishnan, Van Emburgh et al. 2008).  DNA 
methylation is a stable and heritable yet reversible epigenetic trait of 
mammalian genomes (Jaenisch and Bird 2003; Baylin 2005; Baylin and Ohm 
2006; Jirtle and Skinner 2007; Weber and Schubeler 2007; Weidman, Dolinoy 
et al. 2007; Gopalakrishnan, Van Emburgh et al. 2008; Ooi and Bestor 2008).  
CpG dinucleotides are found throughout any eukaryotic organism’s genome.   
The CpG dinucleotides that tend to cluster into islands containing the GC 
content of >55% in a 500-bp region (Turek-Plewa and Jagodzinski 2005; Weber 
and Schubeler 2007).  The status and maintenance of the methylation of CpG 
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islands is a critical factor that affects gene transcription, as CpG islands are 
present in approximately 70% of human gene promoters and/or the first exon of 
many genes (Saxonov, Berg et al. 2006).  It has been known for some time now 
that methylation of CpG islands is common and essential for silencing and 
regulation of many types of DNA sequences (Ooi, O'Donnell et al. 2009).   
It is well accepted that the methylation patterns of a gene promoter are 
crucial to the regulation of the expression of the gene, and a correlation 
between methylation status and gene expression is apparent (Mohn and 
Schubeler 2009).  The general rule of thumb is that if the gene promoter is 
highly methylated, then that gene is silenced.   
Since CpG islands are observed within promoter regions of about ~72% 
of human genes,  methylation of CpG-rich promoters  frequently coincides with 
reduced gene activity (Saxonov, Berg et al. 2006).  Reduced gene expression is 
achieved either directly through disruption of the transcription factor and RNA 
polymerase binding or indirectly through the recruitment of methyl-CpG binding 
domain proteins as subsequent chromatin remodeling (Klose and Bird 2006).     
This silencing method, in which the cell is capable of turning genes on 
and off when needed either in the maintenance of the cell itself or during 
development of the organism, is essential to the survival of the organism.  Also, 
this principle allows for mechanisms within the cell to methylate foreign DNA 
thus not allowing transcription of the foreign DNA to interfere with the normal 
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workings of the cell (Jahner, Stuhlmann et al. 1982).  Thus, besides controlling 
gene expression, DNA methylation suppresses parasitic DNA sequences such 
as transposons and endogenous retroviruses (Esteller 2005).  Interestingly, 
global hypomethylation is a hallmark of all stages of tumor cells with a 20%-
60% decrease in methylated cytosines.  This decrease in methylated DNA 
coincides with the reactivation of transposable elements, mitotic recombination 
(leading to loss of heterozygosity) and aneuploidy (Robertson and Wolffe 2000; 
Robertson 2002; Weber and Schubeler 2007; Weidman, Dolinoy et al. 2007).  
Furthermore, cells lacking the activity of DNMT3b display high levels of 
chromosome aberrations (Xu, Bestor et al. 1999).  Therefore, in a 
hypomethylated environment chromosomal instability increases and genome 
integrity is challenged.   
Under normal conditions (i.e. no introduction of foreign DNA, influence 
of environmental factors, etc.) DNA methylation patterns are very dynamic 
during development of the organism.  This is due to the cell’s need to turn 
genes on and off based on their need during developmental growth of the 
organism.  However, once cells have become differentiated, changes in DNA 
methylation patterns become stagnant and are actually inherited across the 
generations of the cells.  Once a cell has become differentiated, it’s DNA 
methylation patterns are inherited by its progeny in order to conserve the 
appropriate expression of genes required for homeostasis of the tissue, organ 
and the organism overall (Ooi and Bestor 2008; Ooi, O'Donnell et al. 2009).  
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Changes in methylation resulting in hypermethylation or 
hypomethylation of various regions of an organisms’ genome can have a drastic 
effect not only on the cells directly affected, but it can contribute to the 
development of malignant or autoimmune diseases within the organism.  Even 
though the exact mechanism by which DNA methylation changes may 
contribute to carcinogenesis still needs to be precisely defined, it can be 
deduced that not only can DNA methylation changes contribute to genome 
instability, but they may also directly affect the expression of oncogenes and 
other important regulatory genes within the cell.   
  Three main groups of proteins partake in establishing and maintaining 
DNA methylation patterns within mammalian cells. These are DNA 
methyltransferase (DNMT) 1, DNMT3a, and DNMT3b (Goll and Bestor 2005; 
Brenner and Fuks 2006; Gopalakrishnan, Van Emburgh et al. 2008).  DNMT3a 
and DNMT3b are responsible for de novo methylation of sequences. Mutant 
mice lacking either of these genes die within weeks of birth (DNMT3a mutants) 
or are not viable through embryonic stages (DNMT3b mutants) 
(Gopalakrishnan, Van Emburgh et al. 2008).   Contrarily, DNMT1, an enzyme 
that co-localizes to the replication forks, is responsible for maintaining 
methylation patterns of hemi-methylated DNA following replication (Goll and 
Bestor 2005; Jirtle and Skinner 2007; Weber and Schubeler 2007).  DMNT1-/- 
mice are embryonic lethal (Li, Bestor et al. 1992).   
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DNA methylation in cancer and breast cancer 
Numerous studies revealed that abnormal DNA methylation is not just a 
phenomenon that is frequently observed in cancers, but it has become a well-
accepted hallmark of cancer (Cheung, Lee et al. 2009).   Early studies 
conducted in 1983 by Feinberg and Vogelstein (Kovalchuk, Tryndyak et al. 
2007; Cheung, Lee et al. 2009) showed that the human cancer genome (i.e. the 
genomes of various types of cancers from various individuals) is 
hypomethylated on a global basis.  It is currently well-accepted that global DNA 
hypomethylation occurs early in tumorigenesis. DNA hypomethylation makes 
affected cells susceptible not only to genomic instability but also to further 
genetic changes and cellular changes.  Widschwendter’s group found a 
correlation between hypomethylation and tumor progression and cancer 
metastasis in ovarian tumors (Widschwendter, Jiang et al. 2004).  By comparing 
two specific areas of DNA on Chromosome 1 of a variety of ovarian tumors at 
various stages and comparing them to non-neoplastic samples, they 
determined that there was a significant difference in the levels of methylation 
(i.e. the tumorous tissues were hypomethylated) in these areas of the 
chromosome.  They also found that the level of hypomethylation of these areas 
(Sat2 and Sat-alpha) correlates significantly with the tumor metastasis and 
relapse. 
DNA methylation occurs predominantly in the context of CG 
dinucleotides.  It is crucially important for normal development, cell proliferation, 
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and proper maintenance of genome stability (Rountree, Bachman et al. 2001; 
Jaenisch and Bird 2003; Shames, Minna et al. 2007).  DNA methylation is 
associated with an inactive chromatin state and repressed gene expression 
activity (Robertson and Wolffe 2000; Robertson 2002; Klose and Bird 2006). 
Aberrant global DNA methylation is a well-known feature of cancer cells 
(Mattsson, Ruden et al. 1993).  It is frequently characterized by global genome 
hypomethylation, as well as concurrent hypermethylation of selected CpG 
islands within gene promoters (Baylin 2005; Baylin and Ohm 2006; Weidman, 
Dolinoy et al. 2007).  Altered DNA methylation has been linked to the activation 
of transposable elements, elevated chromosome breakage, aneuploidy, 
increased mutation rates and, thus to the phenomena of global genomic 
instability and carcinogenesis (Robertson and Wolffe 2000; Rountree, Bachman 
et al. 2001; Jaenisch and Bird 2003; Weber and Schubeler 2007).  
Altered genome DNA methylation patterns are very important in the 
etiology and pathogenesis of breast cancer (Szyf, Pakneshan et al. 2004; 
Tryndyak, Kovalchuk et al. 2006; Chekhun, Lukyanova et al. 2007).  Two types 
of changes in the DNA methylation pattern occur in breast cancer, global 
genome hypomethylation and regional hypo- and hypermethylation of specific 
genes (Yang, Yan et al. 2001; Szyf, Pakneshan et al. 2004; Ronckers, Erdmann 
et al. 2005).  Until now, most of the research in the field of cancer epigenetics, 
including the epigenetics of breast cancer, has been focused on the role of 
hypermethylation of the promoters of tumor suppressor genes (Fackler, 
McVeigh et al. 2004; Widschwendter, Siegmund et al. 2004; Jones 2005).  In 
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contrast, global DNA hypomethylation, although it was the first epigenetic 
abnormality identified in cancer, has received much less attention (Bernardino, 
Roux et al. 1997; Szyf, Pakneshan et al. 2004).  Not only is DNA 
hypomethylation in cancer correlated withbreast  tumor initiation and 
progression, but it was also found to have a significant correlation with 
histologic grading, disease staging, and tumor size of breast carcinoma 
samples (Soares, Pinto et al. 1999).  It has been well established that both 
types of methylation patterns occur in breast cancer, in that regional 
hypermethylation of certain genes occurs as well as global hypomethylation 
(Szyf, Pakneshan et al. 2004). 
Overall, the role of epigenetic changes in the etiology of radiation-
induced breast cancer is not fully understood. 
MicroRNAome  
In October of 2001, three papers addressing the role of small-temporal 
RNAs (stRNAs) on Caenorhabditis elegans development appeared in Science 
magazine (Lagos-Quintana, Rauhut et al. 2001; Lau, Lim et al. 2001; Lee and 
Ambros 2001).  While stRNAs were known to be involved in the negative 
regulation of protein-coding genes, the finding of over 100 new tiny RNAs 
sequences from three different species, including humans, demonstrated that 
this mechanism may be more conserved and more complex than initially 
perceived.  These newly discovered small RNAs were named microRNAs 
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(miRNAs), and have since become a hotspot for discovery and study of 
developmental processes and disease pathogenesis.  Currently, there are more 
than 700 human miRNAs listed in the miRNA database, miRBase 
(http://microrna.sanger.ac.uk/sequences/), representing >1 % of all genes in the 
human genome.  Furthermore, these miRNAs can potentially target up to one-
third of human coding genes making their role in cellular biology even more 
apparent (Fujita and Iba 2008; Griffiths-Jones, Saini et al. 2008). 
Functional (mature) miRNAs are derived either from three types of loci 
with annotated transcripts (the introns of protein coding genes, the exons of 
non-coding genes, and the introns of non-coding genes) or from intergenic 
regions within the genome (Rodriguez, Griffiths-Jones et al. 2004; Liu, Calin et 
al. 2008; Liu, Spizzo et al. 2008).  MiRNAs within known annotated transcripts 
are under the direct transcriptional control of their host genes.  Intergenic 
miRNAs, however, are under their own control and in most cases are 
transcribed via the action of RNA polymerase II (Fujita and Iba 2008; Liu, Calin 
et al. 2008; Liu, Spizzo et al. 2008).  Approximately 36% of miRNAs in the 
human genome are organized into clusters ≤10kB apart (Griffiths-Jones, Saini 
et al. 2008), and many of these clusters are only 100-1000kB from each other.  
This has led to the discovery that many miRNAs are transcribed together as a 
single transcriptional unit, or polycistron (Fujita and Iba 2008; Griffiths-Jones, 
Saini et al. 2008).  The function of these multi-miRNA polycistrons are thought 
to be for the efficient targeting of a single mRNA transcript, or to target multiple 
transcripts in a signal molecular pathway.  Some of these polycistrons play 
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important roles in cellular proliferation and apoptosis, and dysregulation of these 
miRNAs can perpetuate a cancer phenotype.  
Following transcription, a primary miRNA (pri-miRNA) forms a stem-
loop structure with a double-stranded RNA (dsRNA) stem of ~33 nucleotides 
(Liu, Calin et al. 2008; Liu, Spizzo et al. 2008; Winter, Jung et al. 2009).  This 
dsRNA intermediate is then recognized by the RNaseIII-type enzyme Drosha 
and its dsRNA-binding partner DGCR8/Pasha (Han, Lee et al. 2004; Kim 2005; 
Kim 2005; Liu, Calin et al. 2008; Liu, Spizzo et al. 2008).  This microprocessor 
than excises the dsRNA stem from the pri-miRNA stem loop, creating a 
precursor miRNA (pre-miRNA) (Kim 2005; Kim 2005; Liu, Calin et al. 2008; Liu, 
Spizzo et al. 2008).  The pri- to pre-miRNA cropping also utilizes a number of 
accessory proteins to produce different types, or subsets of miRNAs, allowing 
additional levels of miRNA regulation (Fukuda, Yamagata et al. 2007; Guil and 
Caceres 2007; Winter, Jung et al. 2009).  After excision, the pre-miRNA is 
bound by the nuclear export factors Exportin-5 and RanGTP.  This binding 
functions to stabilize the duplex, protect it from degradation, and transport the 
pre-miRNA to the cytoplasm (Kim 2005; Liu, Calin et al. 2008; Liu, Spizzo et al. 
2008).  
In the cytoplasm, the RNase-III endonuclease Dicer, in association with 
the proteins TRBP, PACT, and AGO2, recognize and bind the pre-miRNA.  This 
stimulates the cleavage of the pre-miRNA ~22-nucleotides from the 3’-OH, and 
produces the mature miRNA duplex with 3’ 2-nucleotide overhangs (Kim 2005; 
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Kim 2005; Liu, Calin et al. 2008; Liu, Spizzo et al. 2008; Winter, Jung et al. 
2009).  The Argonaut (AGO) protein then stimulates the dissociation of one of 
the strands, which is subsequently degraded, leaving a single-stranded 
functional miRNA; however, the exact mechanism of strand-selection in 
mammals has yet to be uncovered.  The Dicer protein then dissociates from the 
complex, creating the active machinery for silencing, termed the miRNA/AGO 
ribonucleoprotein (miRNP), also known as the RNA-induced silencing complex 
(RISC) (Winter, Jung et al. 2009). 
The miRNP use the mature miRNAs as guides to direct silencing in a 
sequence specific manner by binding to target mRNAs at miRNA recognition 
elements (MREs).  These MREs are usually found in the 3’ untranslated region 
(UTR) of the mRNA; however, recent evidence for 5’ UTR binding has also 
been presented (Lytle, Yario et al. 2007).  The exact mechanism of miRNP-
mediated translation inhibition still eludes silencing investigators, but several 
working hypothesis have been suggested.  The most widely accepted putative 
mechanism in mammals occurs at the initiation step of translation (Humphreys, 
Westman et al. 2005; Wakiyama, Takimoto et al. 2007).  
MicroRNAome in cancer and breast cancer 
Regulatory miRNAs and their processing machinery have a great 
impact on cellular differentiation, proliferation, apoptosis, and possibly even on 
the predisposition to cancer (Esquela-Kerscher and Slack 2006; Fabbri, Ivan et 
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al. 2007; Mack 2007).  Extensive studies have documented profound alterations 
of miRNA expression in all major human cancers.  
In cancer microRNAs can act as tumor suppressors or oncogens 
(oncomiRs).  Overexpression and amplification are the main criteria used for 
defining a miRNA as an oncomiR.  The most abundant cancer-related oncomiR 
is miR-21.  This miRNA is up-regulated in over 15 different cancers, including 
some of the most aggressive cancers such as glioblastoma, lymphoma, 
pancreatic, and lung cancers (Ciafre, Galardi et al. 2005; Yanaihara, Caplen et 
al. 2006; Lee, Gusev et al. 2007; Lawrie, Gal et al. 2008).  miR-21 is located on 
chromosome 17 and can act as an oncogene by regulating the tumor-
suppressor genes PTEN (Meng, Henson et al. 2007) and PDCD (Frankel, 
Christoffersen et al. 2008).  Inactivation of miR-21 in several cell lines resulted 
in increased cell death by reactivating caspases (Chan, Krichevsky et al. 2005; 
Si, Zhu et al. 2007), and activation of PTEN (Meng, Henson et al. 2006). 
The miR-17-92 cluster was among the first miRNA groups discovered to 
be deregulated in a number of human tumors, including lymphomas (O'Donnell, 
Wentzel et al. 2005), leukemias (Venturini, Battmer et al. 2007), lung 
(Hayashita, Osada et al. 2005), breast (Hossain, Kuo et al. 2006), and testicular 
(Novotny, Nielsen et al. 2007; Novotny, Sonne et al. 2007) cancers, among 
others.  The miR-17-92 cluster contains six miRNAs that are transcribed 
together as a single polycistron.  Up-regulation of these miRNAs is correlated 
with increased levels of cellular proliferation and decreased levels of apoptosis. 
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The miR-221/222 tandem, located less that 1Kb from each other on 
chromosome X, is an example of an oncomiR cluster.  The aberrant expression 
of this cluster has significance in thyroid carcinoma (He, Jazdzewski et al. 2005; 
Pallante, Visone et al. 2006; Visone, Russo et al. 2007), hepatocellular 
carcinoma (Wong, Lung et al. 2008), pancreatic adenocarcinoma (Bloomston, 
Frankel et al. 2007), non-small lung cancer (Garofalo, Quintavalle et al. 2008), 
and prostate cancer (Mercatelli, Coppola et al. 2008).  The possible oncomiR 
mechanism of miR-221/222 is through the suppression of p27/Kip, a key 
mediator of cell cycle progression inhibitors (Visone, Russo et al. 2007; 
Mercatelli, Coppola et al. 2008; Mayoral, Pipkin et al. 2009).  
Among numerous tumor-suppressor miRNA genes, the most interesting 
are members of the let-7-family, the miR-15a-16-1 cluster, the miR-34 family, 
and the miR-143-145 cluster.  Special characteristics and the mechanisms of 
tumor-suppressor activity of the let-7-family, the miR-15a-16-1 cluster and the 
miR-34 family were recently described in several excellent reviews (Lee and 
Dutta 2009; Ventura and Jacks 2009). 
The lesser known miR-143-145 cluster consists of two miRNAs, miR-
143 and miR-145, that are located ~1500Kb apart within the fragile site 5q33. 
Many cancers exhibit down-regulation of these miRNAs such as colorectal, 
ovarian, breast and lung cancers, chronic lymphocytic leukemia, cervical, 
bladder and prostate cancers (Iorio, Ferracin et al. 2005; Yanaihara, Caplen et 
al. 2006; Akao, Nakagawa et al. 2007; Akao, Nakagawa et al. 2007; Iorio, 
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Visone et al. 2007; Ichimi, Enokida et al. 2009).  The only confirmed target for 
miR-143 is ERK5, which is involved in cell growth promotion and proliferation 
(Wang and Tournier 2006), and overexpression of ERK5 has already been 
detected in several cancers (Mehta, Jenkins et al. 2003; Carvajal-Vergara, 
Tabera et al. 2005).  Other potential tumor-suppressor miRNAs include miR-99, 
miR-100, miR-125a and 125b, miR-126, miR-139 and miR-140.  These miRNAs 
are down-regulated in three or more cancers; and their experimentally 
confirmed targets include ERRB2, ERBB3, vascular cell adhesion molecule 
VCAM1, and histone deacetylase HDAC4(Datta, Kutay et al. 2008; Nasser, 
Datta et al. 2008; Silber, Lim et al. 2008).  
Additionally, several studies have pointed towards a putative role for the 
miRNA processing machinery in tumor cells.  It has recently been shown that 
levels of Ago2 were elevated in breast tumors (Adams, Claffey et al. 2009), and 
that levels of Dicer expression correlated with the clinical stage, lymph node 
status and survival in prostate adenocarcinoma, Burkitt lymphoma and non-
small cell lung carcinomas (Kaul and Sikand 2004; Karube, Tanaka et al. 2005; 
Chiosea, Jelezcova et al. 2006; Chiosea, Jelezcova et al. 2007).  Also, aberrant 
levels of miRNAs have been reported in a variety of human cancers (Fabbri, 
Garzon et al. 2007), including breast cancer (Iorio, Ferracin et al. 2005; 
Foekens, Sieuwerts et al. 2008).  However, the role of microRNAs in genotoxic 
stress response in general and in ionizing radiation-induced mammary gland 
carcinogenesis in particular has yet to be studied in detail. 
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RADIATION EFFECTS ON EPIGENETIC PARAMETERS 
Direct radiation exposure strongly influences epigenetic effectors.  DNA 
damaging agents including IR have been reported to affect DNA methylation 
patterns (Kalinich, Catravas et al. 1989; Tawa, Kimura et al. 1998; Minamoto, 
Mai et al. 1999; Kovalchuk, Burke et al. 2004).  Acute exposures to low LET X-
rays or g-rays were noted to result in global hypomethylation (Kalinich, Catravas 
et al. 1989; Tawa, Kimura et al. 1998).  It was recently shown that the IR 
exposure leads to the profound dose-dependent and sex- and tissue specific 
global DNA hypomethylation (Pogribny, Raiche et al. 2004; Raiche, Rodriguez-
Juarez et al. 2004; Koturbash, Pogribny et al. 2005; Pogribny, Koturbash et al. 
2005; Loree, Koturbash et al. 2006).  Exposure to IR also affects methylation of 
the promoter of the p16 tumor suppressor in a sex- and tissue-specific manner 
(Kovalchuk, Burke et al. 2004).  The DNA hypomethylation observed after 
irradiation was found to be related to DNA repair (Pogribny, Raiche et al. 2004). 
It also correlated with the radiation-induced alterations in the expression of DNA 
methyltransferases, especially de novo methyltransferases DNMT3a and 
DNMT3b (Raiche, Rodriguez-Juarez et al. 2004; Pogribny, Koturbash et al. 
2005).  Most importantly, the radiation-induced global genome DNA 
hypomethylation appeared to be linked to genome instability in the exposed 
tissue (Pogribny, Raiche et al. 2004; Raiche, Rodriguez-Juarez et al. 2004; 
Pogribny, Koturbash et al. 2005; Loree, Koturbash et al. 2006). 
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DNA methylation is closely connected to other components of 
chromatin structure.  Although much attention has been given to the radiation-
induced changes in DNA methylation, histones have been largely overlooked.  
Among the histone modifications that change upon radiation exposure, 
phosphorylation of histone H2AX is being studied most intensively.  Histone 
H2AX, a variant of histone H2A, is rapidly phosphorylated at Ser139 upon the 
induction of DNA strand breaks by irradiation, and it can be effectively 
visualized within repair foci using phosphor-specific antibodies (Sedelnikova, 
Pilch et al. 2003).  Recent studies have also indicated that radiation-induced 
global loss of DNA methylation may correlate with the changes in histone 
methylation, specifically with the loss of histone H4 lysine trimethylation 
(Pogribny, Koturbash et al. 2005).  
The data on the IR effects of microRNAome are in their infancy (Ishii 
and Saito 2006; Marsit, Eddy et al. 2006).  However, it has been determined 
that exposure to IR results in significant changes to the microRNAome.  These 
changes can be detected as early as several hours after exposure to IR 
(Ilnytskyy, Zemp et al. 2008; Koturbash, Zemp et al. 2008; Ilnytskyy, Koturbash 
et al. 2009), and can persist for days, weeks  (Koturbash, Zemp et al. 2008; 
Tamminga, Kathiria et al. 2008; Ilnytskyy, Koturbash et al. 2009), and even 
months (Koturbash, Boyko et al. 2007) post exposure.  Analysis of miRNA 
profiles from different tissues after treatment with IR has shown tissue-
dependent and sex-specific mechanisms of radiation-induced miRNA regulation 
(Koturbash, Boyko et al. 2007; Ilnytskyy, Zemp et al. 2008; Koturbash, Zemp et 
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al. 2008; Tamminga, Kathiria et al. 2008).  Some miRNAs have shown species-, 
time-, and tissue-independent regulation of expression. miR-194, for example, 
was found up-regulated at early and late post exposure time points in both the 
spleen and blood of rats and mice (Koturbash, Boyko et al. 2007; Ilnytskyy, 
Koturbash et al. 2009).  Interestingly, miR-194 was also up-regulated in non-
exposed bystander tissue after low (0.5 Gy) and high (20 Gy) doses of radiation 
(Koturbash, Boyko et al. 2007; Ilnytskyy, Koturbash et al. 2009).  This finding 
might suggest that despite variability of miRNA response to IR, there are also 
some common mechanisms that are not limited to sex, dose or tissue 
specificity.  The exact roles of miRNAs in radiation-induced carcinogenesis still 
need to be delineated. 
BACKGROUND INFORMATION FOR THE PROJECT 
RADIATION-INDUCED EPIGENETIC CHANGES 
Most of studies published on IR-induced epigenetic changes have been 
conducted by Dr. Olga Kovalchuk’s group (Kovalchuk, Burke et al. 2004; 
Kovalchuk, Hendricks et al. 2004; Pogribny, Raiche et al. 2004; Raiche, 
Rodriguez-Juarez et al. 2004; Koturbash, Pogribny et al. 2005; Pogribny, 
Koturbash et al. 2005; Koturbash, Baker et al. 2006; Koturbash, Rugo et al. 
2006; Loree, Koturbash et al. 2006; Koturbash, Boyko et al. 2007; Koturbash, 
Kutanzi et al. 2008; Koturbash, Zemp et al. 2008).  They have shown that single 
dose and fractionated direct IR exposure leads to profound, persistent, dose-
dependent, and sex- and tissue-specific DNA hypomethylation (Pogribny, 
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Raiche et al. 2004; Pogribny, Koturbash et al. 2005) which is related to DNA 
repair (Pogribny, Raiche et al. 2004) and is linked to IR-induced alterations in 
the expression of DNA methyltransferases (Raiche, Rodriguez-Juarez et al. 
2004).  Furthermore, they reported that whole-body IR-exposure leads to a 
profound loss of histone H4K20 trimethylation (Pogribny, Koturbash et al. 2005).  
They have also proven that IR-induced bystander effects in distant naïve 
tissues, as well as changes in the progeny of exposed parents are 
epigenetically regulated (Koturbash, Baker et al. 2006).  Kovalchuk’s group has 
demonstrated that direct and bystander IR triggers a significant and sex-specific 
deregulation of the microRNAome and alters levels of the miRNA-processing 
enzyme Dicer and components of the RNA-induced silencing complex (RISC) 
(Koturbash, Zemp et al. 2008).  Furthermore, Kovalchuk’s lab has shown that 
direct and localized IR exposure results in altered levels of miRNAs in the blood 
of exposed animals (Koturbash, Boyko et al. 2007). 
EPIGENETIC DYSREGULATION IN ESTROGEN–INDUCED MAMMARY GLAND 
CARCINOGENESIS 
In collaboration with Dr. Pogribny’s group, the Kovalchuk laboratory has 
conducted several studies to address the role of epigenetic changes in breast 
carcinogenesis.  They have analyzed the nature and role of epigenetic changes 
in estrogen-induced breast carcinogenesis using a rat model.  During their 
study, they found that the development of estrogen-induced mammary gland 
tumors was associated with substantial alterations in global and locus-specific 
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DNA methylation levels, the loss of histone H3K9 and H4K20 trimethylation, the 
changed expression of DNA and histone methyltransferases and significantly 
altered miRNA expression profiles.  MicroRNA changes observed in rat 
mammary tumors were similar to those reported in human breast cancer. 
Importantly, microRNAome deregulation preceded pathological changes 
(Kovalchuk, Tryndyak et al. 2007). 
EPIGENETIC AND GENETIC CHANGES IN RAT MAMMARY GLAND EXPOSED TO X-
RAYS 
The Kovalchuk group also explored the effects of IR on rat mammary 
gland and was the first to show that IR exposure resulted in notable epigenetic 
changes.  Specifically, they found that a single application of 5 Gy of X-rays 
resulted in a strong and significant loss of DNA methylation in mammary tissue 
of rats 6 and 96 hours after exposure.  Global DNA hypomethylation was 
paralleled with significant reductions in levels of maintenance methyltransferase 
DNMT1, de novo DNA methyltransferases DNMT3a and 3b, and methyl-binding 
proteins 6 and 96 hours after exposure (Loree, Koturbash et al. 2006).  Having 
seen profound changes in DNA methylation after IR exposure, researchers 
decided to further substantiate their analysis and study the long-term effects of 
irradiation on the rat mammary gland.  In a preliminary set of experiments 
conducted by the Kovalchuk laboratory, juvenile female rats were randomly 
assigned to one of the following treatment groups (n=6 per group): sham 
treated controls and IR-exposed treated group.  IR treated animals were 
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exposed to 2.5 Gy of X-rays (LD50 for rat 7.5 Gy).  Morphological analysis 
revealed that IR exposure resulted in an increased vascularization of rat 
mammary gland tissue in all animals 6 weeks after exposure.  By 18 weeks post 
exposure, all animals developed fibroadenomas, and one out of 6 animals 
exhibited adenocarcinoma of the breast. Irradiation also led to significant global 
DNA hypomethylation 6 weeks after IR exposure that was paralleled by a 
decrease in cellular levels of DNMT3a and a decrease in trimethylation of lysine 
20 of histone H4.  Epigenetic changes were also paralleled by increased levels 
of proliferation and apoptosis.  In addition, the group found that radiation 
exposure caused significant alterations in miRNA levels.  Irradiation resulted in 
up-regulation of 11 and down-regulation of 5 miRNAs in rat mammary tissue 6 
weeks after exposure.  
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HYPOTHESES 
The literature and preliminary research conducted by Dr. Kovalchuk’s 
laboratory have shown that: (i) ionizing radiation is a mammary gland 
carcinogen, yet mechanisms of IR-induced mammary gland carcinogenesis are 
unknown; (ii) high-dose IR exposure exerts profound global epigenetic DNA 
methylation and miRNA changes in exposed mammary gland tissue, and these 
changes may be important in breast carcinogenesis. 
While this research has provided extremely pertinent information in the 
area of mammary gland radiation responses and carcinogenesis, there are still 
mysteries that remain unsolved.  It is important to analyze the effects of low 
radiation doses on mammary gland.  The role of the microRNAome in low dose 
IR-induced breast carcinogenesis needs to be delineated.  The exact 
contribution of DNA methylation to the generation and maintenance of IR-
induced genome instability and carcinogenesis in mammary gland also needs to 
be established.  
We hypothesized that the methylome and microRNAome 
dysregulation that occurs in mammary gland upon IR exposure may be a 
mechanism involved in mammary gland IR responses.  We suggest that IR 
effects will be dose and X-ray energy level specific.  
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EXPERIMENTAL MODEL 
Rodent, specifically rat models of mammary gland carcinogenesis are 
well-established and well-accepted as an initial point to begin the understanding 
of breast carcinoma in humans.  The rat model provides a unique opportunity 
for the study of breast cancer initiation and progression (Shull, Spady et al. 
1997; Harvell, Strecker et al. 2000; Shull, Pennington et al. 2001; Li, Weroha et 
al. 2004; Ronckers, Erdmann et al. 2005).  Rat models have been widely used 
to address the incidence and mechanisms of chemical- or IR-associated breast 
carcinogenesis, because their lifespan (100–150 weeks) is relatively short, and 
they develop mammary tumors (Bartstra, Bentvelzen et al. 1998; Bartstra, 
Bentvelzen et al. 1998; Bartstra, Bentvelzen et al. 2000; Rudel, Attfield et al. 
2007).  ACI, Long Evans and WAG/Rij rat strains are the most widely used in 
experiments.  These strains exhibit a spontaneous incidence of mammary 
carcinoma ranging from 10-20% (Bartstra, Bentvelzen et al. 1998; Bartstra, 
Bentvelzen et al. 1998; Bartstra, Bentvelzen et al. 2000).  This baseline 
incidence is somewhat higher than the reported incidence of breast cancer in 
Canadian women, which is approximately 8-10% (Bartstra, Bentvelzen et al. 
2000).  However, in subpopulations of women who are at an increased risk of 
breast cancer the incidence may be as high as 50–80% (Bartstra, Bentvelzen et 
al. 2000).  Therefore, the spontaneous incidence of mammary cancer in rats 
may be considered realistic, in view of the situation that occurs in humans. 
Importantly, rats are physiologically relevant models for studying human 
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breast cancer, since mammary gland carcinogenesis in rats is remarkably 
similar to human breast cancer (Shull, Spady et al. 1997; Bartstra, Bentvelzen 
et al. 2000; Harvell, Strecker et al. 2000; Shull, Pennington et al. 2001).  Using 
rat models provides an excellent opportunity to dissect the process of 
carcinogenesis, identify the exact sequence of carcinogenic events, and to 
define the role of epithelial and stromal cells in IR responses and IR-induced 
carcinogenesis.  Therefore, in this study we used the Long Evans (LE) rat 
strain.  LE rats exhibit a low spontaneous incidence of mammary carcinoma and 
are susceptible to radiation carcinogenesis.  
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DOSE RANGE 
Doses were determined based on epidemiologic literature and our data. 
Specifically, studies of atomic bomb survivors (Tokunaga, Land et al. 1994), 
patients repeatedly subjected to fluoroscopy (Boice, Preston et al. 1991; Howe 
and McLaughlin 1996), women irradiated for mastitis or other benign breast 
diseases (Shore, Hildreth et al. 1986; Mattsson, Ruden et al. 1993), and 
Hodgkin’s disease patients treated with radiation therapy (Hancock, Tucker et 
al. 1993; Bhatia, Robison et al. 1996) clearly show a carcinogenic risk with IR 
doses between 1 and 5 Gy.  These populations received either a single dose or 
fractionated doses of IR. Breast cancer screening involves much lower doses, 
typically 1–4 mGy per mammogram.  Mammography screening yields a total 
cumulative dose of approximately 0.1 Gy over a period of 20 years (Bartstra, 
Bentvelzen et al. 2000).  As the effects of such small doses are unknown, 
breast cancer risk estimates due to mammography are extrapolated from 
observations on risks from higher doses, assuming that these risks would 
decrease linearly with decreasing a total dose.  However, it has been proven 
that linearity does not apply to very low doses (Brenner, Sawant et al. 2002).  
Low dose exposure may be much more dangerous than previously thought.  
Therefore, it is very important to compare the effects of high, intermediate and 
low doses of IR on mammary gland carcinogenesis. 
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MATERIALS AND METHODS 
ANIMAL EXPOSURE  
In this study we used six-week-old female LE rats.  Handling and care 
of animals was in strict accordance with the recommendations of the Canadian 
Council for Animal Care and Use.  The procedures were approved by the 
University of Lethbridge Animal Welfare Committee prior to the commencement 
of the experiment.  Animals were housed in a virus-free facility and given food 
and water ad libitum. 
For the study, six-week-old female LE rats were randomly assigned to 
one of the following treatment groups and received either intermediate–high (1 
Gy) or low (0.1 Gy) IR doses (n=30 per group; 5 animals per each dose/time 
point).  An intermediate-high dose is close to the dose received by healthy 
breasts during radiotherapy and/or CT diagnostics.  A low dose is slightly higher 
than the cumulative dose from multiple mammography screens.  Furthermore, 
the low dose groups will be split into an intermediate-high (80kVp) or low 
(30kVp) energy X-ray groups.  High energy rays are used for therapy and CT 
scans, while low energy rays are used for mammography. 
Group 1: 80kVp X-rays, 1 Gy – Intermediate-high dose/high energy;  
Group 2: 80kVp X rays, 0.1 Gy – Low dose/high energy; 
Group 3: 30kVp X rays, 0.1 Gy – Low dose/low energy; and  
Group 4: Sham treated controls. 
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Five animals per group were sacrificed by Euthansol overdose at 3 
hours, 1 week, 2 weeks, 6, 20 and 26 weeks after irradiation to study early and 
delayed effects.  Statistical analysis of the experimental design conducted by 
our NCTR colleagues indicates that this design has an 80% probability of 
detecting differences at p<0.05 level.  
TISSUE SAMPLING AND PROCESSING  
Paired inguinal mammary glands were quickly excised upon sacrifice.  
One gland was frozen immediately and stored at -80°C for subsequent 
molecular analysis.  The contralateral gland was observed with 
transluminescence, which allowed the orientation of ducts and alveolar lobules 
to be visualized (Adams, Claffey et al. 2009).  Specimens were fixed in 10% 
neutral buffered formalin for 48 hours, processed, embedded in paraffin, 
sectioned at 4 microns, and mounted on glass slides.  Sections were stained 
with hematoxylin and eosin (H&E) for histopathological examination. 
DNA METHYLATION 
Total DNA was prepared from rat mammary gland tissue of exposed 
and control animals using Qiagen DNAeasy Kit (Qiagen, Mississauga, Ontario) 
according to the manufacturer’s protocol.  Levels of the global genome DNA 
methylation in mammary gland tissue were measured by the HpaII /MspI 
cytosine extension assay.  HpaII that cleaves CCGG sequences when internal 
cytosine residues are unmethylated on both strands.  MspI is an isoschizomer 
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of HpaII which cleaves CCGG sites in DNA regardless of CpG methylation 
status.  The cytosine extension assay and the determination of the absolute 
percent of double-stranded unmethylated CCGG sites was conducted as 
previously described (Pogribny, Raiche et al. 2004; Pogribny, Koturbash et al. 
2005; Koturbash, Baker et al. 2006). 
In brief, total DNA was prepared from mammary gland tissues using 
Qiagen DNAeasy Kit (Qiagen, Mississauga, Ontario) according to the 
manufacturer’s protocol.  DNA (1 μg) was digested overnight with a 10-fold 
excess of HpaII endonuclease according to manufacturers protocol (New 
England Biolabs, Beverly, MA).  A second DNA aliquot (1 μg) was digested with 
methylation-insensitive isoschizomer MspI, which cleaves CCGG sites in DNA 
regardless of CpG methylation status, to serve as a control for the digestion 
efficiency.  Undigested DNA served as a background control. 
The single nucleotide extension reaction was performed in 25 μg of 
DNA, 1X PCR bufferII, 1.0 mM MgCl2, 0.25 units of Taq DNA polymerase 
(Fisher Scientific, Ottawa, ON), [3H]dCTP (57.4 Ci/mmol) (Perkin Elmer, 
Boston, MA) and incubated at 55°C for 1 h, then immediately placed on ice.  
Duplicate aliquots (25μl) from each reaction were placed on Whatman DE-81 
ion-exchange filters and washed three times 10 minutes with gentle agitation 
with sodium phosphate buffer (0.5 M, pH 7.0) at room temperature.  The filters 
were dried and processed by scintillation counting (Beckman Counter).  
Background label incorporation was subtracted from enzyme-digested samples 
and results were expressed as relative [3H]-dCTP incorporation/1μg of DNA or 
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as percent change from control (Pogribny, Raiche et al. 2004; Raiche, 
Rodriguez-Juarez et al. 2004; Pogribny, Koturbash et al. 2005). 
The absolute percent of double-stranded unmethylated CCGG sites 
was calculated by relating the data of HpaII and MspI digests.  DNA methylation 
changes in the exposed cohorts were related to the age-matched controls. 
MICRORNA ANALYSIS 
Total RNA was extracted from rat mammary gland tissues using TRIzol 
Reagent (Invitrogen, Burlington, Ontario) according to the manufacturer's 
instructions.  Tissue from 3 animals per group was used for the analysis.  The 
miRNA microarray analysis was performed by LC Sciences (Houston, TX).  
In brief, ten micrograms of total RNA were size-fractionated (<200 
nucleotides) by using a mirVana kit (Ambion, Austin, TX).  Poly-A tails were 
added to the RNA sequences at the 3′ ends using a poly(A) polymerase, and 
nucleotide tags were then ligated to the poly-A tails.  The tagged RNAs were 
then hybridized to the dual-channel microarray μParaFlo microfluidics chips (LC 
Sciences) containing 439 miRNA probes to rat and mouse miRNAs and then 
labeled with tag-specific dendrimer Cy3 and Cy5 fluorescent dyes.  Dye 
switching was performed to eliminate the dye bias.  The detection probes 
melting temperature was balanced by incorporating varying numbers of 
modified nucleotides with the increased binding affinities.  Hybridization images 
were collected using a GenePix 4000B laser scanner (Molecular Devices, 
Sunnyvale, CA), and then digitized using the Array-Pro image analysis software 
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(Media Cybernetics, Silver Spring, MD).  The maximum signal level of 
background probes was 180.  A miRNA detection signal threshold was defined 
as twice the maximum background signal. 
Normalization was performed with a cyclic LOWESS (locally weighted 
regression) method to remove system-related variations, as previously 
described (Bolstad, Irizarry et al. 2003; Pogribny, Tryndyak et al. 2007).  Data 
adjustments included data filtering, log 2 transformation, and gene centering 
and normalization.  The t-test analysis was conducted the different irradiated 
groups (IR dose or energy level) groups and their respective age-matched 
control groups.  MicroRNAs with p-values < 0.05 were selected for cluster 
analysis. 
WESTERN IMMUNOBLOTTING 
Western immunoblotting for PACT and beta-actin was conducted using 
rat mammary gland tissue of exposed and control animals as described before 
(Koturbash et al, 2006b; Pogribny et al, 2005) using the anti-PACT (1:500, 
Santa Cruz Biotechnology, CA) and anti-actin (1:2000, Santa Cruz 
Biotechnology) antibodies.  Antibody binding was revealed by incubation with 
horseradish peroxidase-conjugated secondary antibodies (Santa Cruz 
Biotechnology) and the ECL Plus immunoblotting detection system (Amersham, 
Baie d'Urfé, Québec). Chemiluminescence was detected by Biomax MR films 
(Eastman Kodak, New Haven, CT). Signals were quantified using NIH ImageJ 
1.63 Software and normalized to both GAPDH and the Mr 50,000 protein which 
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gave consistent results. Protein levels in the exposed cohorts were related to 
the age-matched controls. 
RNA ISOLATION 
In this study, the tissues were homogenized in Trizol Reagent (Invitrogen, 
CA, USA).  RNA isolation was performed according to the Qiagen RNeasy Mini 
Kit column (Qiagen, CA, USA) protocol.  The RNA was quantified and the 
quality was checked by electrophoresis (Ding, Xie et al. 2008). 
 
RNA LABELING AND MICROARRAY HYBRIDIZATION 
RNA labeling and microarray hybridization were performed by Genome 
Quebec and McGill University Innovation Centre.  Illumina Rat Ref-12 
Expression BeadChip (Illumina, Inc.) rat whole-genome expression arrays were 
used in this study.  Three biological replicates were used per each experimental 
group.  In brief, each RNA sample was amplified using the Ambion Illumina RNA 
amplification kit with biotin UTP (Enzo) labeling.  The Ambion Illumina RNA 
amplification kit uses T7 oligo(dT) primer to generate single stranded cDNA 
followed by a second strand synthesis to generate double-stranded cDNA, 
which is then column purified.  In vitro transcription was conducted to synthesize 
biotin-labeled cRNA using T7 RNA polymerase.  The cRNA was column purified 
and checked for size and yield.  cRNA was hybridized using standard Illumina 
protocols with streptavidin-Cy3 (Amersham, Piscataway, NJ, USA).  Slides were 
scanned on an Illumina Beadstation and analyzed using BeadStudio (Illumina, 
Inc) (Ding, Xie et al. 2008). 
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Normalization, clustering and significance analysis were done by 
Genome Quebec and McGill University Innovation Centre as previously 
described (Ding, Xie et al. 2008). 
 
STATISTICAL ANALYSIS 
Statistical analysis was performed using MS Excel 2007 and JMP5 
software packages. 
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RESULTS AND DISCUSSION 
 
EXPERIMENT 1 - ANALYSIS OF GLOBAL DNA METHYLATION IN RADIATION-
EXPOSED RAT MAMMARY GLAND TISSUES 
Tumour cells harbour numerous genomic as well as epigenomic 
alterations (Feinberg and Tycko 2004).  Furthermore, epigenetic changes are 
known to play a central role in tumorigenesis.  Epigenetic changes seen in 
cancer cells include global loss of DNA methylation paralleled by a pronounced 
regional hypo- and hypermethylation (Feinberg and Vogelstein 1983; Flatau, 
Bogenmann et al. 1983; Gama-Sosa, Slagel et al. 1983; Jones and Baylin 
2002; Feinberg 2004; Feinberg and Tycko 2004; Tryndyak, Kovalchuk et al. 
2006). 
 
Global DNA hypomethylation was the first epigenetic abnormality that 
was reported in cancer cells.  Overall, DNA hypomethylation is known to be a 
hallmark of cancer (Feinberg and Vogelstein 1983; Feinberg and Vogelstein 
1983; Flatau, Bogenmann et al. 1983; Gama-Sosa, Midgett et al. 1983; Gama-
Sosa, Slagel et al. 1983; Feinberg 2004; Tryndyak, Kovalchuk et al. 2006).  A 
very pronounced global DNA hypomethylation was reported in human breast, 
liver, skin, colorectal and many other cancers.  Furthermore, global DNA 
hypomethylation occurred at very early premalignant stages of carcinogenesis 
(Fearon and Vogelstein 1990; Bernardino, Roux et al. 1997; Soares, Pinto et al. 
1999; Lin, Hsieh et al. 2001; Fraga, Herranz et al. 2004; Szyf, Pakneshan et al. 
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2004; Hu, Yao et al. 2005; Karpinets and Foy 2005).  Therefore, global genome 
and locus-specific hypomethylation was proposed to be a key step in 
carcinogenesis, and recent works by the groups of professor Jaenisch has 
reported that DNA hypomethylation plays a causative role in tumorigenesis 
(Gaudet, Hodgson et al. 2003; Yamada, Jackson-Grusby et al. 2005).  Global 
DNA hypomethylation has been associated with chromosomal and genomic 
instability (Lengauer, Kinzler et al. 1997; Chen, Pettersson et al. 1998; Vilain, 
Vogt et al. 1999; Ehrlich 2002).  Since genome instability and DNA 
hypomethylation occur very early during cancer predisposition and 
development, DNA hypomethylation  may in turn cause genome instability by 
promoting loss of heterozygosity in some key regions that regions contain 
tumour suppressor and DNA repair genes (Ehrlich 2002; Feinberg and Tycko 
2004; Tryndyak, Kovalchuk et al. 2006).  Additionally, it has been proposed that 
DNA hypomethylation may facilitate aberrant gene expression, lead to 
activation of oncogenes and thus, promote carcinogenesis. 
 
Exposure to DNA damaging agents, including IR, was reported to cause 
global DNA hypomethylation is various tissues in vivo (Koturbash, Pogribny et 
al. 2005; Pogribny, Koturbash et al. 2005; Ilnytskyy, Koturbash et al. 2009).  
Furthermore, exposure to high therapeutic doses of IR led to induction of 
significant DNA hypomethylation in the rat mammary gland tissue.  Effects of 
low doses of IR on global DNA methylation in the mammary gland tissue 
remained unexplored.  With this in mind we set out to analyse the role of low 
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and intermediate –level IR doses on the DNA methylation in rat mammary gland 
tissue. 
 
In the course of this study, six-week-old female LE rats were randomly 
assigned to one of the following treatment groups and received either 
intermediate–high (1 Gy) or low (0.1 Gy) IR doses.  An intermediate-high dose 
is close to the dose received by healthy breasts during radiotherapy and/or CT 
diagnostics.  A low dose is slightly higher than the cumulative dose from 
multiple mammography screens.  Furthermore, the low dose groups were split 
into a high (80kVp) or low (30kVp) energy X-ray groups.  High energy rays are 
used for therapy and CT scans, while low energy rays are used for 
mammography.  Animals were sacrificed at 3 hours, 1 week, 2 weeks, 6 weeks, 
20 weeks and 26 weeks after exposure to radiation to study early and delayed 
effects. 
 
We employed a well-established and sensitive HpaII/MspI-based 
cytosine extension assay that measures the proportion of CCGG that had lost 
methyl groups on both strands.  HpaII is a methylation-sensitive restriction 
endonuclease that cleaves CCGG sequences when internal cytosine residues 
are unmethylated on both strands and leaves a 5'-guanine overhang after 
cleavage that can be used for subsequent single nucleotide extension with 
[3H]dCTP.  While HpaII cleaves CCGG sequences when internal cytosine 
residues are unmethylated on both strands, its isoschizomer MspI cleaves 
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CCGG sites in DNA regardless of CpG methylation status.  The absolute 
percent of double-stranded unmethylated CCGG sites can be calculated by 
relating the data of HpaII and MspI digests (Pogribny, James et al. 2004). 
Because the vast majority of the frequently occurring HpaII tetranucleotide 
recognition sequences are constitutively methylated in vivo, an increase in 
cleavage at these sites is an indicator of genome-wide hypomethylation  
(Pogribny, James et al. 2004; Koturbash, Pogribny et al. 2005; Tryndyak, 
Kovalchuk et al. 2006; Tryndyak, Kovalchuk et al. 2007). 
 
We noted that whole body low- and intermediate doses of X-ray 
exposure resulted in a statistically significant increase in the absolute percent of 
unmethylated CCGG sites in rat mammary gland tissues 3 hours after 
irradiation.  Application of 1 Gy of X-rays resulted in the most pronounced DNA 
methylation loss seen as a significant decrease in the level of methylated 
CCGG sites in the genome (Figure 1).  Interestingly, the loss of global DNA 
methylation that was observed 3 hours after exposure  returned to normal 1 
week after exposure and further stayed at the same levels up to 2, 20 and 26 
weeks after irradiation.  IR-induced global loss of DNA methylation seen 3 hours 
after exposure was a very interesting finding. 
 
Several mechanisms may contribute to DNA hypomethylation.  These 
may include a reduction of cellular methylation capacity, altered expression and 
activity of DNA methyltransferases, inability of mammalian maintenance DNA 
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methyltransferase DNMT1 to methylate double-stranded unmethylated CpG 
sites.  Furthermore, it may be linked to DNA damage and presence of 
unrepaired lesions in DNA.  These lesions interfere with methylation ability of 
DNA methyltransferases (Koturbash, Pogribny et al. 2005). 
 
Indeed, IR is a well-documented potent DNA damaging agent that can 
induce formation of a variety of DNA lesions and activate DNA repair 
mechanisms.  DNA damage was previously reported to interfere with 
methylation ability of DNA methyltransferases (Turk, Laayoun et al. 1995; 
Panayiotidis, Rancourt et al. 2004).  Moreover, during repair DNA synthesis 
cellular DNA polymerases incorporate cytidine, but not methyl-cytidine. 
Consequently, the presence and repair of radiation-induced DNA lesions may 
result in DNA hypomethylation.  Therefore, the observed DNA hypomethylation 
may be associated with IR-induced DNA damage.  By 1 week after exposure 
damage was repaired and DNA methylation levels were restored. 
 
Interestingly, we have previously seen that exposure to 5 Gy of X rays, 
a high therapeutic-range dose, caused global DNA hypomethylation 6 hours 
and 96 hours after exposure.  Our current data correlate with these previous 
findings.  One can predict that it takes longer than 96 hours, but less than a 
week to fully repair DNA damage and to restore DNA methylation.  Additionally, 
the IR-induced DNA methylation changes seen in this study were less 
pronounced than those seen before (Loree, Koturbash et al. 2006).  Indeed, 
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exposure to 5 Gy of X-rays  caused much more significant changes in DNA 
methylation (Loree, Koturbash et al. 2006).  The differences may be due to the 
different doses, and consequently, different DNA damaging potential of the 
applied IR doses. 
 
Yet, the most interesting finding is an observation of significant DNA 
hypomethylation promoted by exposure to very low doses of IR – 0.1 Gy, both 
at high (80kVp) and low energy (30kVp) levels.  The changes induced by the 
30kVp rays were the most intriguing, since this energy range is widely used in 
mammography.  It was previously reported that the low energy mammography 
rays were more hazardous, per unit dose, than high-energy X- or γ-rays 
(Brenner, Sawant et al. 2002).  Low-energy X-rays exhibited a higher 
oncotransformation potential than 200kVp X-rays, suggesting that low-energy 
X-rays used in mammography are considerably more biologically active than 
previously thought (Frankenberg, Kelnhofer et al. 2002; Frankenberg, Kelnhofer 
et al. 2002).  The latter finding is consistent with the data on significant 
increases in chromosome aberrations induced by low energy X-rays (Brenner 
and Amols 1989).  All the aforementioned biological processes may be affected 
by the altered DNA methylation levels.  Yet, future studies are needed to 
establish the mechanistic links between low-dose and low energy radiation-
induced DNA hypomethylation and chromosome aberrations and onco-
transformation of the cells. 
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EXPERIMENT 2 - ANALYSIS OF IR-INDUCED GENE EXPRESSION IN RAT 
MAMMARY GLAND TISSUES 
Having seen significant changes in DNA methylation 3 hours after 
exposure to IR and the restoration of DNA methylation levels seen 1 week after 
exposure, we decided to further analyse the IR-induced changes in gene 
expression.  Indeed, DNA hypomethylation is known to cause gene expression 
changes. 
 
To analyze gene expression, we employed a highly sensitive Illumina 
microarray featuring Bead Array technology (Fan, Gunderson et al. 2006; 
Kennerly, Ballmann et al. 2008; Anantamongkol, Charoenphandhu et al. 2010).  
Our analysis revealed that exposure to 0.1 Gy/30kVp x-rays altered expression 
of 401 genes 3 hours after x-ray irradiation.  Exposure to 0.1Gy/80kVp of X-rays 
affected the expression of 135 genes, and exposure to 1 Gy/80kVp x-rays – of 
389 genes (Figure 2). 
 
The fact that  low dose and low energy X-ray exposure was a stronger 
inducer of gene expression changes agrees well with the previous finding of the 
pronounced biological effectiveness of low energy mammography-type X-rays 
(Frankenberg, Kelnhofer et al. 2002; Frankenberg, Kelnhofer et al. 2002).  The 
exact roles of the observed gene expression changes in the mammary gland 
responses to mammography-type X-rays need to be further elucidated.  By 2 
weeks after exposure, only 21, 9 and 90 genes were affected  by exposure to 
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0,1 Gy/30kVp, 0.1 Gy/80kVp and 1 Gy/8-kVp X-rays, respectively (Figure 2). 
The lists of identified genes are presented in tables 1-6. 
 
Interestingly, amongst the genes that changed their expression 3 hours 
after exposure to 0.1 Gy/30kVp, 0.1 Gy/80kVp and 1.0 Gy/80kVp X-rays 43 
genes were commonly affected (Table 7).  These genes were involved in a wide 
variety of cellular processes, such as regulation of apoptosis, cell cycle control, 
DNA repair and metabolism, cell-cell signalling, oxidative stress responses and 
many others.  
 
One of the interesting genes affected by all the studied doses was 
growth factor receptor-bound protein 7 (Grb7).  The product of this gene 
belongs to a small family of adaptor proteins that are known to interact with a 
number of receptor tyrosine kinases and signalling molecules, including 
HER2/neu (Shen and Guan 2004; Holt and Daly 2005; Bai and Luoh 2008; 
Lucas-Fernandez, Garcia-Palmero et al. 2008; Nadler, Gonzalez et al. 2010; 
Wang, Chan et al. 2010).  Specifically, GRB7 is an SH2-domain adaptor protein 
that binds to receptor tyrosine kinases and provides the intra-cellular direct link 
to the Ras proto-oncogene (Depetris, Wu et al. 2009). 
 
Aberrant over-expression of Grb7 has been found in numerous human 
cancers, including ovarian, pancreatic, liver and breast cancer, lymphoma, 
osteosarcoma and testicular germ cell tumours (Eppert, Wunder et al. 2005; 
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Maqani, Belkhiri et al. 2006; Goddard, McIntyre et al. 2007; Itoh, Taketomi et al. 
2007; Kishimoto, Kitamura et al. 2007; Myllykangas, Junnila et al. 2008; Nadler, 
Gonzalez et al. 2010; Wang, Chan et al. 2010).  Its role in breast cancer is very 
important.  Human GRB7 is located on the long arm of chromosome 17, next to 
the ERBB2 (alias HER2/neu) proto-oncogene.  GRB-7 is amplified concurrently 
with HER-2/Neu in most of breast cancer with chromosome 17q11–21 
amplification.  GRB-7 gene amplification is associated with its over-expression 
(Stein, Wu et al. 1994; Tanaka, Mori et al. 1997; Vinatzer, Dampier et al. 2005).   
In breast cancer, over expression of Grb7 defines a subset of breast cancer 
patients with decreased survival,  indicating that Grb7 might be a valuable 
prognostic marker and drug target (Nadler, Gonzalez et al. 2010). 
 
We have seen a profound decrease in the levels of GRB7 mRNA after 
irradiation.  Given a strong oncogenic potential of Grb7, its down-regulation 
after radiation exposure may be viewed as a protective strategy.  In the future, 
the role of this gene in mammary gland radiation responses still has to be 
defined.  The role of this gene in mammary gland radiation responses still has 
to be defined.  We have seen a profound decrease in the levels of GRB7 mRNA 
after irradiation.  Given a strong oncogenic potential of Grb7, its down-
regulation after radiation exposure may be viewed as a protective strategy. 
 
Another gene that exhibited altered expression after irradiation was 
AKT1 or protein kinase B (PKB).  Activation of AKT1 plays a pivotal role in 
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fundamental cellular functions such as cell proliferation and survival by 
phosphorylating a variety of substrates.  Akt1 is implicated in regulation of 
cellular survival pathways by suppressing apoptotic processes (Franke, Hornik 
et al. 2003; Song, Ouyang et al. 2005).  It also regulated protein synthesis 
(Yang, Tschopp et al. 2004).  As such, Akt1 has been implicated as a major 
factor in many types of cancer, including breast cancer (Toker and Yoeli-Lerner 
2006; Arendt and Schuler 2008; Gonzalez and McGraw 2009; Jiang, Enomoto 
et al. 2009).  
 
Interestingly, the phosphatidylinositol-3-kinase (PI3-K)/ AKT pathway is 
associated with radiation resistance.  Activation of PI3-K/AKT is associated with 
intrinsic radiosensitivity, tumour cell proliferation, and hypoxia (Zhan and Han 
2004; Valerie, Yacoub et al. 2007; Bussink, van der Kogel et al. 2008; 
Schuurbiers, Kaanders et al. 2009).  Overall, mounting  evidence suggests that 
the AKT pathway is a major contributor to radioresistance (Zhan and Han 
2004).  Interestingly, AKT1 expression and phosphorylation was up-regulated in 
the rat mammary gland tissue after exposure to 5 Gy of X-rays (Loree, 
Koturbash et al. 2006).  
 
We also noted that low dose-low energy radiation exposure altered the 
levels of KIT, FOS and JUNB oncogenes.  KIT, or CD117  is a  receptor 
tyrosine kinase involved in cell signal transduction in several cell types 
(Roussidis, Theocharis et al. 2007).  The role of KIT, its expression and function 
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in breast cancer is a very controversial subject (Roussidis, Theocharis et al. 
2007).  Some researchers  propose that the loss of KIT expression is linked with 
tumor progress, whereas other reports indicate not only its expression but also 
the key role of KIT in breast cancer progression (Roussidis, Theocharis et al. 
2007).  Interestingly, recent studies reported differential expression of c-Kit in 
human breast tissue in response to therapeutic irradiation (Westbury, Reis-Filho 
et al. 2009).  Specifically, a reduction in c-Kit and an increase in ESR1 
(oestrogen receptor-alpha) mRNA and protein levels were observed  in 
irradiated samples as compared to non-irradiated ones (Westbury, Reis-Filho et 
al. 2009).  More analysis is clearly needed to define the role(s) of this gene in 
mammary gland responses to therapeutic and diagnostic irradiation and overall 
to mammary gland IR-induced carcinogenesis. 
 
JunB is an important member of the AP-1 (activator protein-1) family of 
transcription factors.  Strikingly, JUNB plays a dual role in the regulation of the 
cell cycle.  On the one hand it acts as a cell proliferation inhibitor, a senescence 
inducer and a tumour suppressor.  It exerts its actions through its positive 
influence on the p16INK4alpha cyclin-dependent kinase inhibitor and its 
negative effect on cyclin D1 in G1-phase.  On the other hand, JUNB can 
promote  cell division via stimulation of cyclin A2 expression in the S-phase 
(Piechaczyk and Farras 2008).  JUNB was shown to be increased in murine 
spleen tissue after exposure to IR (Wan and Ishihara 2004).  It was also 
activated in irradiated normal skin fibroblasts (Martin, Vozenin et al. 1997). 
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Exposure to gamma irradiation dramatically increased the levels of Fos and 
JunB in rat fetal brain (Borovitskaya, Evtushenko et al. 1996).  Yet, its precise 
roles in radiation responses in general and mammary gland radiation responses 
in particular need to be further deduced. 
 
c-Fos is a cellular proto-oncogene and a member of the immediate 
early gene family of transcription factors (van Straaten, Muller et al. 1983; 
Abate, Baker et al. 1993; Kerppola, Luk et al. 1993).  Its transcription is up-
regulated in response to many extracellular signals and factors, including 
ionizing radiation (Weichselbaum, Hallahan et al. 1994).  FOS dimerizes with 
the JUN proteins and forms the AP-1 transcription factor which regulates 
expression of a wide variety of genes involved in control of cellular proliferation 
and differentiation.  The AP-1 complex plays a key part  in transformation and 
progression of cancer (Milde-Langosch 2005; Matthews, Colburn et al. 2007; 
Verde, Casalino et al. 2007; Durchdewald, Angel et al. 2009).  
 
Recent studies have demonstrated that the early response genes such 
as c-jun and c-fos are induced following exposure of mammalian cells to 
ionizing radiation.  The products of these genes may  regulate downstream 
genes that are important in the adaptation of cells and tissues to radiation-
induced stress (Weichselbaum, Hallahan et al. 1994).  The exact roles of AP-1 
transcription complex members in low dose radiation responses of mammary 
gland tissue need to be further discerned. 
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EXPERIMENT 3  - EFFECTS OF RADIATION EXPOSURE ON RAT MAMMARY 
GLAND MICRORNAOME 
Ionizing radiation (IR) is an invaluable diagnostic and treatment tool, yet 
it is also a well-documented cytotoxic agent and a potential carcinogen (Trosko 
1996; Little 2000).  IR exposure causes a number of alterations in the irradiated 
cells and tissues, including induction of DNA strand breaks (Little 2000; 
Barcellos-Hoff and Nguyen 2009; Cwikel, Gidron et al. 2010; Mah, El-Osta et al. 
2010), altered gene expression (Little 2000; Barcellos-Hoff 2008), cell cycle 
arrest, apoptosis (Nagar, Smith et al. 2003; Ahmed 2004; Gupta and Ahmed 
2004) as well as a number of epigenetic changes resulting in genomic instability 
(Morgan, Day et al. 1996; Trosko 1996; Barcellos-Hoff 2001; Bourguignon, 
Gisone et al. 2005; Kovalchuk 2008; Kovalchuk and Baulch 2008).  Epigenetic 
changes have been increasingly recognized as key elements of radiation 
responses (Pogribny, Raiche et al. 2004; Raiche, Rodriguez-Juarez et al. 2004; 
Pogribny, Koturbash et al. 2005; Loree, Koturbash et al. 2006; Kovalchuk 2008; 
Kovalchuk and Baulch 2008; Tamminga, Koturbash et al. 2008).  
 
Amongst those, the least studied is the newly emerged mechanism of 
epigenetic control mediated through the involvement of small regulatory RNAs 
(Niwa and Slack 2007; Filipowicz, Bhattacharyya et al. 2008; Grosshans and 
Filipowicz 2008).  There are a number of functional classifications of small 
regulatory RNAs, and among them, microRNAs (miRNAs) are of a particular 
interest (Niwa and Slack 2007).  MiRNAs are evolutionally conserved, small, 
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single-stranded, non-protein-coding RNA molecules which are presently 
recognized as major regulators of gene expression (Niwa and Slack 2007; 
Filipowicz, Bhattacharyya et al. 2008; Grosshans and Filipowicz 2008).  
 
By regulating gene expression miRNAs impact numerous cellular 
processes, such as differentiation, proliferation, apoptosis, and even 
predisposition to cancer (Esquela-Kerscher and Slack 2006; Garzon, Fabbri et 
al. 2006; Slack and Weidhaas 2006).  Indeed, aberrant levels of miRNAs have 
been reported in a variety of human cancers, including breast cancer (Iorio, 
Ferracin et al. 2005; Esquela-Kerscher and Slack 2006; Slack and Weidhaas 
2006; Calin, Liu et al. 2007; Fabbri, Garzon et al. 2007; Fabbri, Ivan et al. 
2007).  However, less is knows about the roles of  miRNAs in response to 
genotoxic stress in general, and to IR, in particular (Cha, Seong et al. 2009; 
Ilnytskyy, Koturbash et al. 2009; Shin, Cha et al. 2009; Shin, Cha et al. 2009; 
Simone, Soule et al. 2009). 
 
With this in mind we analyzed the effects of low and intermediate doses 
of IR on microRNA expression in rat mammary gland tissue.  As in the previous 
experiment, six-week-old female LE rats were randomly assigned to one of the 
following treatment groups and received either intermediate–high (1 Gy) or low 
(0.1 Gy) IR doses of radiation. An intermediate-high dose is close to the dose 
received by healthy breasts during radiotherapy and/or CT diagnostics.  A low 
dose is slightly higher than the cumulative dose from multiple mammography 
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screens.  Furthermore, the low dose groups were split into a high (80kVp) or 
low (30kVp) energy X-ray groups.  High energy rays are used for therapy and 
CT scans, while low energy rays are used for mammography.  
 
Analysis of the rat mammary gland microRNAome revealed a number 
of intriguing patterns.  We found that exposure to ionizing radiation resulted in 
gross microRNAome perturbations in the rat mammary gland tissue.  Seven 
microRNAs exhibited altered expression 3 hours after exposure, as defined by 
ANOVA analysis (Figure 3). These were miR-155, miR-184, miR-30c-2*, miR-
324-3p, miR-690 and miR-146b.  Amongst these microRNAs, the most 
interesting one was miR-155. The level of this microRNA was significantly 
increased in rat mammary gland tissue 3 hours after exposure to 0.1 Gy/80kVp 
and 1 Gy/80kVp (Figure 3). 
 
MiR-155 is a well-known oncogenic miRNA.  Elevated expression of 
miR-155 is a predictor of a poor survival in pancreatic tumors (Greither, 
Grochola et al. 2010).  Over-expression of miR-155 was shown to significantly 
down-regulate the core mismatch repair  proteins, hMSH2, hMSH6  and hMLH1 
leading to the induction of a mutator phenotype and microsatellite instability in 
colon cancer (Valeri, Gasparini et al. 2010).  More importantly, Valeri and 
colleagues have clearly shown that MSI colorectal tumors with unknown cause 
of mismatch repair inactivation exhibited a pronounced over-expression of miR-
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155 (Valeri, Gasparini et al. 2010).  Therefore, miR-155 is indispensible for 
regulation of mismatch repair in tumor cells (Valeri, Gasparini et al. 2010). 
 
Recent data published by Rai and co-authors have provided a proof 
that miR-155 directly targets the bone morphogenetic protein (BMP)-responsive 
transcriptional factor SMAD5 and thus partakes in  TGF-beta pathway and 
lymphomagenesis (Rai, Kim et al. 2010).  MiR-155 also targets inositol 
phosphatase SHIP1 to promote TNF alpha-dependent growth of B cell 
lymphomas (Pedersen, Otero et al. 2009).  Interestingly, miR-155 is also crucial 
for B-cell maturation and its activation appears to be controlled through the 
extracellular signalling-regulated kinase (ERK) and c-Jun N-terminal kinase 
(JNK) pathways but not the p38 pathway (Yin, Wang et al. 2008).  Additionally, 
miR-155 is thought to provide a crucial link between inflammation and cancer 
(Tili, Croce et al. 2009; Banerjee, Schambach et al. 2010).  Recent data also 
implicated miR-155 in hepatocarcinogenesis.  MiR-155 was shown to be 
significantly up-regulated at early stages of hepatocarcinogenesis induced by 
choline-deficient and amino acid-defined diet in C57BL/6 mice.  This up-
regulation was trans-activated by nuclear factor kappa B (NF-kappaB) (Wang, 
Majumder et al. 2009). 
 
MiR-155 is very important in breast cancer (O'Day and Lal 2010; Zhu, 
Hu et al. 2010).  It was shown to function as an oncomiR by targeting the 
suppressor of cytokine signaling 1 gene (SOCS1) (Jiang, Zhang et al. 2010).  
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MiR-155 regulates cell survival, growth and chemosensitivity of breast cancer 
cells by targeting FOXO3a (Kong, He et al. 2010). 
 
Kong and colleagues reported that TGF-beta induced miR-155 
expression and promoter activity through the function of Smad4.  Additionally, 
they have shown that the knockdown of miR-155 inhibited the TGF-beta-
induced epithelial-mesenchymal transition, cell migration and invasion.  The role 
of miR-155 in the TGF-beta-induced EMT may position it as an important target 
for future therapeutic breast cancer interventions (Kong, Yang et al. 2008). 
 
Ectopic expression of miR-155 was proven to induce the proliferation of 
breast cancer cells, and, more importantly, to promote development of tumors in 
nude mice (Jiang, Zhang et al. 2010).  Moreover, the expression of miR-155 is 
strongly up-regulated in primary breast cancer, especially in patients with ER 
and PR+ tumors (Zhu, Hu et al. 2010).  Not only was this miRNA identified in 
breast cancers, it was also found in the serum samples of women affected by 
this disease (Zhu, Qin et al. 2009).  Yet, most importantly, this oncogenic 
miRNA was shown to be upregulated in MO59K cells after radiation exposure 
(Chaudhry, Sachdeva et al. 2010).  
 
As the next step of our analysis we set out to identify novel predicted 
targets of miR-155 that may be pertinent for radiation responses and mammary 
gland carcinogenesis.  To further discern the mode of action of miR-155 and to 
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gain more insight to its role in mammary gland radiation responses, we set out 
to identify novel yet unknown targets of this miRNA.  A number of computer 
programs are used to analyze potential regulation and biological functions of 
miRNAs.  Assaying putative targets in the rodent model is achieved using 
TARGETSCAN 4.0.  This program uses the 5’ ends of miRNAs, known as seed 
sites, to look for perfect to near-perfect alignment with the 3’UTR of genes 
(Lewis, Shih et al. 2003; Lewis, Burge et al. 2005).  Additionally, computer-
predicted target genes for differentially expressed miRNAs will be determined 
using miRNA target databases MiRanda (Memorial Sloan-Kettering Cancer 
Center) and Sanger (Welcome Trust Sanger Institute) (http://cbio.mskcc.org and 
http://microrna.sanger.ac.uk/sequences/). 
 
Amongst the novel targets, we were especially interested in those 
genes that regulate transcription, apoptosis, cell cycle and DNA repair, 
chromatin structure and epigenetic regulation.  Analysis identified Transcription 
factor PU.1 (Sfpi1), Ras-related protein Rab-9 (Rab-9A), RAB30, member RAS 
oncogene family (Rab30), Retinoblastoma-like protein 2 (Rbl2) and  Mitogen-
activated protein kinase 6 (Mapk6). 
 
To confirm targeting and translational repression of selected mRNAs by 
miR-155, we tested the ability of miR-155 to target 3’UTRs of selected genes in 
a well-established luciferase reporter assay.  To examine whether the selected 
genes were indeed functionally targeted by miR-155, the segments of Sfpi1 and 
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Rab9a 3′-UTRs containing the miR-155 complementary sites were cloned into 
the 3′-UTR of a luciferase reporter system.  The resulting reporter vectors were 
transfected into the MCF-7 cells together with the transfection controls and miR-
155. 
 
Figure 4 shows that miR-155 inhibited the luciferase activity from the 
construct with the Sfpi1 and Rab9a 3′-UTR segments in a concentration-
dependent manner.  There was no change in the luciferase reporter activity 
when the cells were co-transfected with the negative control (scrambled 
oligonucleotides).  In the future, it will be important to define the role of these 
miR-155 targets in the radiation responses of mammary gland tissue.  
 
Rab proteins play key roles in intracellular transport(Simons and Zerial 
1993).  Specifically, Rab9, a Ras-like GTPase, is involved in protein transport 
from late endosomes to the Golgi network (Shapiro, Riederer et al. 1993).  Its 
roles in radiation responses, cancer and breast cancer are still to be defined.  
The precise targets of Rab9 signaling have yet to be defined. 
 
PU.1 (Sfpi1), a pleiotropic regulator, is expressed from the first 
embryonic stages (Olive, Wagner et al. 2007).  Sfpi1 gene encodes an ETS-
domain transcription factor that activates gene expression during myeloid and 
B-lymphoid cell development.  It encodes a nuclear protein that binds to a 
purine-rich sequence known as the PU-box found near the promoters of target 
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genes.  Spfi1 is a putative proto-oncogene involved in murine virus-induced 
acute erythroleukemias (Levesque, Mattei et al. 1991).  Graded repression of 
PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate 
and is important for hematopoiesis (DeKoter, Kamath et al. 2007; Chou, 
Khandros et al. 2009).  Interestingly, it was recently reported that the loss of 
PU.1/Sfpi1 leads to the induction of acute myeloid leukemia (Rosenbauer, 
Wagner et al. 2004).  Induction of miR-155 observed in this experiment may in 
turn lead to the loss of its target PU.1/Sfpi1.  The contribution of this miR-155- 
PU.1/Sfpi1interaction in breast cancer and mammary gland radiation responses 
still have to be further analyzed. 
 
 
Amongst other miRNAs that exhibited altered expression in radiation-
exposed mammary gland tissue, we noted miR-184.  This miRNA was 
upregulated after exposure to 0.1 Gy/80kVp and 1 Gy/80kVp.  miR-184 was 
down-regulated in prostate cancer(Schaefer, Jung et al. 2010).  Yet, it acts as a 
potential oncogenic microRNA in squamous cell carcinoma of tongue (Wong, 
Liu et al. 2008).  Its roles it breast cancer and radiation responses still have to 
be defined. 
 
One week after exposure only 3 microRNAs exhibited differential 
expression.  These were miR-101a, miR-28* and miR-30a* (Figure 5).  
Amongst those miR-101a deserves a special mention (Tanaka, Haneda et al. 
2009).  This microRNA controls mammary gland development by regulating 
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cyclooxygenase-2 expression (Tanaka, Haneda et al. 2009).  Tanaka and 
colleagues have recently reported a significant increase of miR-101a 
expression throughout differentiation and involution of mammary gland tissue 
(Tanaka, Haneda et al. 2009).  Over expression of this miRNA also inhibited 
HC11 cell proliferation and influenced the cellular levels of cyclooxygenase 2 
(Chakrabarty, Tranguch et al. 2007; Daikoku, Hirota et al. 2008; Tanaka, 
Haneda et al. 2009).  IR is known to induce inflammation and increase Cox2 
levels (Ning, Chen et al. 2007; Nandi, Ulasov et al. 2008).  Therefore, an 
increase of miR-101a after irradiation may be viewed as an anti-inflammatory 
strategy.  Future studies are needed to dissect the roles of miR-101a and Cox2 
in the mammary gland radiation responses. 
 
Interestingly, 6 weeks after exposure to 0.1 Gy/30kVp and 1 Gy/80kVp 
of X-rays we noted a significant down-regulation of miR-434-3p and miR-214 
(Figure 6).  miR-214 is an important oncomiR.  High expression of miR-214 was 
associated with unfavourable outcome in gastric cancer (Ueda, Volinia et al. 
2010).  This miRNA induces cell survival and cisplatin resistance in ovarian 
tumors by targeting PTEN (Yang, Kong et al. 2008).  miR-214 regulates the 
expression of MEK3 and JNK1 (Yang, Chen et al. 2009).  PTEN, MEK and 
JNK1 are important regulators of radiation responses (Dent, Yacoub et al. 2003; 
Caron, Yacoub et al. 2005) therefore, in the future it would be very important to 
dissect the role of miR-214 in radiation effects.  
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Most interestingly, we have seen microRNAome changes 6 weeks after 
exposure to a very low dose of low energy X-rays.  The mechanisms of these 
changes will have to be established and their cellular and organismal 
repercussions need to be further established. 
 
To control translation of target mRNAs, miRNAs must associate with 
RNA-induced silencing complex (RISC) proteins such as Argonaute (Ago), 
PACT (a protein activator of the interferon-induced protein kinase), fragile X 
mental retardation protein (FxR), TudorSN  or other proteins (Jin, Zarnescu et 
al. 2004; Chendrimada, Gregory et al. 2005; Scadden 2005; Lee, Hur et al. 
2006; Liang, Ridzon et al. 2007).  Our analysis revealed that radiation exposure 
altered PACT levels in rat mammary gland tissue 1 week after irradiation 
(Figure 7). 
 
PACT is a vital member of the RISC complex, which interacts directly 
with Dicer and contributes to its stabilization (Lee, Hur et al. 2006).  Data on the 
cellular effects of PACT are relatively scarce.  The up-regulation of PACT was 
reported in bronchoalveolar carcinoma, and higher levels of PACT were 
considered a poor prognostic factor (Roh, Kwak et al. 2005).  Our previous 
studies have shown that radiation exposure altered PACT levels in the directly 
irradiated and distant bystander tissue (Koturbash, Zemp et al. 2008).  The 
biological repercussions of these changes still need to be delineated.  Overall, 
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the role of PACT in genotoxic stress responses, carcinogenesis and radiation-
induced breast carcinogenesis has yet to be established. 
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GENERAL DISCUSSION AND CONCLUSIONS 
The possible adverse health effects of low-dose IR exposure constitute a 
growing concern.  IR is a well-accepted breast carcinogen.  Average IR-
exposure doses linked to the development of breast cancer range between 0.2 
and 20 Gy (Ronckers, Erdmann et al. 2005).  Therefore, there has been much 
debate about benefits and risks of diagnostic mammography (Brenner, Sawant 
et al. 2002; Berrington de Gonzalez and Reeves 2005; Nekolla, Griebel et al. 
2008).  Specifically, patients are often concerned about the potential risks of 
mammography-related IR-exposure and carcinogenesis (Brenner, Sawant et al. 
2002; Berrington de Gonzalez and Reeves 2005; Constine, Tarbell et al. 2008; 
Nekolla, Griebel et al. 2008).  The doses from mammography are low, typically 
around 3 mGy of 26-30kVp X-rays (Kruger and Schueler 2001; Brenner, 
Sawant et al. 2002).  Overall, mammography screening yields a total cumulative 
dose of approximately 0.1 Gy over a period of 20 years (Bartstra, Bentvelzen et 
al. 2000).  The effects of such small doses are unknown; however the main 
concern is that these low energy rays are more hazardous, per unit dose, than 
high-energy X- or γ-rays (Brenner, Sawant et al. 2002). 
 
Therefore, we set out to investigate the effects of either intermediate–
high (1 Gy) or low (0.1 Gy) IR doses on rat mammary gland tissue.  An 
intermediate-high dose is close to the dose received by healthy breasts during 
radiotherapy and/or CT diagnostics.  A low dose is slightly higher than the 
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cumulative dose from multiple mammography screens.  Furthermore, we 
compared the effects of intermediate-high (80kVp) or low (30kVp) energy X-ray 
groups. High energy rays are used for therapy and CT scans, while low energy 
rays are used for mammography.  
 
We investigated the IR-related DNA methylation, gene expression and 
microRNA expression patterns mammary gland tissue of rats.  The rat model 
provides a unique opportunity for the study of breast cancer initiation and 
progression and for the analysis of mammary gland radiation effects (Shull, 
Spady et al. 1997; Harvell, Strecker et al. 2000; Shull, Pennington et al. 2001; 
Li, Weroha et al. 2004; Ronckers, Erdmann et al. 2005).  Importantly, rats are 
physiologically relevant models for studying human breast cancer, since 
mammary gland carcinogenesis in rats is remarkably similar to human breast 
cancer (Shull, Spady et al. 1997; Bartstra, Bentvelzen et al. 2000; Harvell, 
Strecker et al. 2000; Shull, Pennington et al. 2001). 
 
We have demonstrated that exposure to 0.1 Gy/30kVp, 0.1 Gy/80 kVp 
and 1Gy/80kVp X-rays leads to noticeable DNA methylation changes, gene 
expression changes and microRNAome alterations in the rat mammary gland.   
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The main conclusions of the present study are: 
(i) Radiation exposure led to the global genome hypomethylation that 
occred 3 hours after exposure and diminished by 1 week after exposure;  
(ii) Radiation exposure resulted in significant changes in radt 
transcriptome, where 401 genes were differentially expressed in the mammary 
gland tissue of rat exposed to low mammaography-like X-rays 90.1 Gy/30kVp);  
(iii) Radiation exposure altered microRNAome of mammary gland tissue.  
 
Radiation-induced mammary gland carcinogenesis is a poorly 
understood and multifaceted process.  The precise mechanisms leading to 
predisposition and development of IR-induced breast cancer remain obscure. 
Furthermore, the evidence for the carcinogenic potential of low-dose and low-
energy X0rays still has to be confirmed.  Importantly, our study proves that 
exposure to intermediate–high (therapy-like) or low (mammography-like) IR 
doses alters several pivotal cellular processes and pathways (DNA methylation, 
transcriptome and microRNAome), each of which can potentially contribute to 
cancer predisposition.  
 
This thesis is the first to show the loss of DNA methylation in the 
mammary gland tissue exposed to low dose and low energy X-rays. 
Importantly, the DNA methylation changes were seen 3 hours after irradiation, 
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and the patterns restored by 1 week after exposure.  We suggest that low dose 
IR-induced DNA methylation changes are related to IR-induced DNA damage.  
 
According to the epigenetic hypothesis of cancer predisposition and 
initiation, genetic and epigenetic changes may play complementary rather than 
contradictory parts in carcinogenesis and interact in such a manner that 
epigenetic alterations may significantly influence effect of initial genetic insults 
and DNA damage (Feinberg 2004; Loree, Koturbash et al. 2006).  
 
Our current results showing radiation-induced DNA hypomethylation in 
exposed mammary gland provide additional experimental support for this 
hypothesis.  
 
Another important finding of our study is the occurrence of profound gene 
expression changes in the IR-exposed mammary gland tissues.  We noted that 
low dose – low energy X-rays induced a very profound alteration in gene 
expression.  Changes induced by 0.1Gy/30kVp X-rays were more drastic that 
those induced by intermediate-high X-rays.  Interestingly, many genes were 
induced in all three exposure groups.  We noted that low and intermediate 
doses of X-rays changes he expression of several important proto-oncogenes 
implicated in breast carcinogenesis.  The roles of genes such as Grb7, Akt 1, 
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JunB and others in radiation responses of mammary gland tissue need to be 
further investigated. 
 
Overall, the observed transcriptome changes may be further explored for 
their potential usability as low dose IR biomarkers. 
 
The changes in miRNAs expression in the rat mammary glands induced 
by IR exposure constitute another novel and important outcome of this thesis. 
miRNAs are small non-coding RNAs that function as key negative regulators of 
gene expression (Taft, Pang et al. ; Voorhoeve).  Aberrant levels of miRNAs 
have been shown in a variety of human cancers including breast cancer.  This 
observation suggested that deregulation of miRNAs expression may play an 
important role in the pathogenesis of human tumours.  However the dynamics 
of miRNA changes during pre-malignant and early predisposition stages have 
not been studied.  Our analysis has defined several miRNAs that changes heir 
expression in response to mammary glands radiation exposure.  One of them is 
an important oncogenic miRNA – miR155.  We have identified two novel targets 
for miR-155: Spfi1 and Rab 9.  Future studies are required for the analysis of 
the roles of the identified radiation responsive miRNAs and their targets in 
radiation-induced effects in mammary glands. 
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In the future our results may serve as a road map for the analysis of rat 
mammary gland radiation responses.  Furthermore, the list of low dose 
radiation-responsive genes and miRNAs may be used as source for potential 
biomarkers of low dose radiation exposure. 
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FIGURES 
 
Figure 1. Radiation-induced DNA methylation changes in the rat mammary gland tissue. 
The levels of global genome DNA methylation in mammary glands of irradiated rats were 
measured by the HpaII/MspI cytosine extension assay. HpaII that cleaves CCGG sequences 
when internal cytosine residues are unmethylated on both strands. MspI is an isoschizomer of 
HpaII that cleaves CCGG sites in DNA regardless of CpG methylation status. The absolute 
percent of double-stranded unmethylated CCGG sites was calculated by relating the data of 
HpaII and MspI digests. Data are presented as mean values ± SD, p<0.05, Student’s s t-test. 
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Figure 2. Venn diagrams of genes differentially expressed after radiation treatment. 
 
mRNA gene lists were generated from array data obtained from Illumina.  Genes shown were 
differentially expressed in mammary tissue when compared to age-matched controls at 3 hours 
and 2 weeks after exposure to ionizing radiation.  Genes represented met the following 
statistical criteria: -1 > log 2 Fold Change > 1, p < 0.05.  
3 hours after exposure
2 weeks after exposure
72 
 
 
 
 
 
Figure 3. MiRNAs that were differentially expressed in the mammary gland tissues of rats 
3 hours after exposure to X-rays.  
Hierarchical clusters of differentially expressed miRNA genes in mammary glands of rats 
exposed to 0.1 Gy/30kVp, 0.1 Gy/80kVp and 1 Gy/80kVp  X-rays (as determined by ANOVA). 
Each miRNA listed is differentially expressed between control and exposure groups (P < 0.05). 
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Figure 4. mir-155 directly targets PU.1 (Sfpi1), Rab 9.  
Graph shows a dose-dependent inhibition of Sfpi1, Rab 9 expression in the luciferase assay 
after transfection of the HEK293 cells with miR-155 or a negative control. 
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Figure 5. MiRNAs that were differentially expressed in the mammary gland tissues of rats 
1 week after exposure to X-rays.  
Hierarchical clusters of differentially expressed miRNA genes in mammary glands of rats 
exposed to 0.1 Gy/30kVp, 0.1 Gy/80kVp and 1 Gy/80kVp  X-rays (as determined by ANOVA). 
Each miRNA listed is differentially expressed between control and exposure groups (P < 0.05). 
 
 
 
 
 
 
 
 
75 
 
 
 
 
 
 
 
 
 
Figure 6. MiRNAs that were differentially expressed in the mammary gland tissues of rats 
6 weeks after exposure to X-rays.  
Hierarchical clusters of differentially expressed miRNA genes in mammary glands of rats 
exposed to 0.1 Gy/30kVp, 0.1 Gy/80kVp and 1 Gy/80kVp  X-rays (as determined by ANOVA). 
Each miRNA listed is differentially expressed between control and exposure groups (P < 0.05). 
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THESIS SUPPLEMENT - TABLES 
Table 1. List of genes differentially expressed 3 hours after exposure to 0.1 Gy of 30kVp X –
rays 
Symbol Entrez Gene Name Fold Change (log2) 
AADAT  aminoadipate aminotransferase -1.32306 
 ABCD2  ATP-binding cassette, sub-family D 
(ALD), member 2 
1.465818 
 ACBD4  acyl-Coenzyme A binding domain 
containing 4 
1.01609 
 ACSL1  acyl-CoA synthetase long-chain 
family member 1 
1.333228 
 ACTN4  actinin, alpha 4 -1.88544 
 AKT1  v-akt murine thymoma viral 
oncogene homolog 1 
-2.00113 
 ALCAM  activated leukocyte cell adhesion 
molecule 
-1.44256 
 ALDH9A1  aldehyde dehydrogenase 9 family, 
member A1 
-1.40758 
 ANXA8   annexin A8 -2.3041 
 AOC3  amine oxidase, copper containing 3 
(vascular adhesion protein 1) 
1.213536 
 ASNS  asparagine synthetase 1.534154 
 ASRGL1  asparaginase like 1 1.37079 
 ATAD1  ATPase family, AAA domain 
containing 1 
-1.09237 
 AXL  AXL receptor tyrosine kinase -1.04192 
 BASP1  brain abundant, membrane 
attached signal protein 1 
-1.43783 
 BAT2  HLA-B associated transcript 2 -1.34704 
 BCKDHA  branched chain keto acid 
dehydrogenase E1, alpha 
polypeptide 
-1.45539 
 BCL2L14  BCL2-like 14 (apoptosis facilitator) -2.3221 
 C6  complement component 6 1.307153 
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 CACNB3  calcium channel, voltage-
dependent, beta 3 subunit 
-1.36291 
 CAP1  CAP, adenylate cyclase-associated 
protein 1 (yeast) 
-3.18319 
 CAPNS1  calpain, small subunit 1 -1.46997 
 CAPZB  capping protein (actin filament) 
muscle Z-line, beta 
-1.74502  
 CAV1  caveolin 1, caveolae protein, 22kDa -2.38332 
 CD14  CD14 molecule -1.44376 
 CD24  CD24 molecule -3.39208 
 CD99 (includes 
EG:4267) 
 CD99 molecule -2.04683 
 CD99 (includes 
EG:652929) 
 CD99 antigen -2.04683 
 CD99 (includes 
EG:673094) 
 CD99 antigen -2.04683 
 CDH1  cadherin 1, type 1, E-cadherin 
(epithelial) 
-1.85582 
 CEBPA  CCAAT/enhancer binding protein 
(C/EBP), alpha 
-1.5754 
 CES2 (includes 
EG:234671) 
 carboxylesterase 2 1.574427 
 CES2 (includes 
EG:8824) 
 carboxylesterase 2 (intestine, liver) 1.574427 
 CFI  complement factor I -2.60558 
 CGREF1  cell growth regulator with EF-hand 
domain 1 
1.637981 
 CHDH  choline dehydrogenase -1.28076 
 CHST1  carbohydrate (keratan sulfate Gal-
6) sulfotransferase 1 
-1.97386 
 CITED1  Cbp/p300-interacting transactivator, 
with Glu/Asp-rich carboxy-terminal 
domain, 1 
-2.73422 
 CLCA2 (includes 
EG:362052) 
 chloride channel calcium activated 
2 
-1.77928 
 CLCA2 (includes 
EG:80797) 
 chloride channel calcium activated 
2 
-1.77928 
 CLCA2 (includes 
EG:9635) 
 chloride channel accessory 2 -1.77928 
 CLDN3  claudin 3 -3.61524 
 CLDN4  claudin 4 -1.9394 
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 CLDN8  claudin 8 -1.27788 
 CLSTN1  calsyntenin 1 -1.09001 
 CLU  clusterin -1.0997 
 CMTM8  CKLF-like MARVEL 
transmembrane domain containing 8 
-2.07703 
 COL15A1  collagen, type XV, alpha 1 1.41071 
 COL1A1  collagen, type I, alpha 1 1.335132 
 CPA1  carboxypeptidase A1 (pancreatic) 1.468828 
 CRABP2  cellular retinoic acid binding protein 
2 
-1.43875 
 CRB3  crumbs homolog 3 (Drosophila) -1.83786 
 CREB3L4  cAMP responsive element binding 
protein 3-like 4 
-1.58633 
 CSN1S2B 
(includes 
EG:12992) 
 casein alpha s2-like B -4.25836 
 CSN1S2B 
(includes 
EG:317712) 
 casein alpha s2-like B -4.25836 
 CSNK1G2  casein kinase 1, gamma 2 -1.11246 
 CSPG4  chondroitin sulfate proteoglycan 4 1.660326 
 CTNNB1  catenin (cadherin-associated 
protein), beta 1, 88kDa 
-2.04875 
 CX3CL1  chemokine (C-X3-C motif) ligand 1 -1.80034 
 CXCL1  chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating 
activity, alpha) 
-1.07518 
 CYP24A1  cytochrome P450, family 24, 
subfamily A, polypeptide 1 
-3.41509 
 DDB1  damage-specific DNA binding 
protein 1, 127kDa 
-1.65652 
 DUOX1  dual oxidase 1 -1.34404 
 EGR1  early growth response 1 -1.38779 
 EHD2  EH-domain containing 2 -1.52507 
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 EIF5A  eukaryotic translation initiation 
factor 5A 
-3.66073 
 EMP3  epithelial membrane protein 3 1.078284 
 EPN1  epsin 1 -1.11735 
 EZR  ezrin -2.05972 
 FAH  fumarylacetoacetate hydrolase 
(fumarylacetoacetase) 
1.688517 
 FAM63A  family with sequence similarity 63, 
member A 
-1.15296 
 FBLN2  fibulin 2 -3.23629 
 FGG  fibrinogen gamma chain -2.53046 
 FOS  FBJ murine osteosarcoma viral 
oncogene homolog 
-1.60993 
 GALNT3  UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 
(GalNAc-T3) 
-2.45352 
 GATA3  GATA binding protein 3 -2.32743 
 GDI1  GDP dissociation inhibitor 1 -2.05166 
 GJA1  gap junction protein, alpha 1, 43kDa -1.22583 
 GJB2  gap junction protein, beta 2, 26kDa -2.56185 
 GLG1  golgi apparatus protein 1 -1.84073 
 GPD1  glycerol-3-phosphate 
dehydrogenase 1 (soluble) 
1.293394 
 GPX1  glutathione peroxidase 1 -1.47802 
 GRB7  growth factor receptor-bound 
protein 7 
-1.40115 
 GSR  glutathione reductase -1.4085 
 GSTT1  glutathione S-transferase theta 1 1.448635 
 GYS2  glycogen synthase 2 (liver) 1.08806 
 HMGB2  high-mobility group box 2 -1.91899 
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 HMGCS2  3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 
(mitochondrial) 
-1.81203 
 HOXC10  homeobox C10 1.486303 
 IL18  interleukin 18 (interferon-gamma-
inducing factor) 
-2.00545 
 IL1R2  interleukin 1 receptor, type II 1.610613 
 IRX2  iroquois homeobox 2 -2.86173 
 ITGA7  integrin, alpha 7 1.998909 
 JUNB  jun B proto-oncogene -1.35211 
 JUP  junction plakoglobin -1.32729 
 KCNK1  potassium channel, subfamily K, 
member 1 
-2.68387 
 KCNK3  potassium channel, subfamily K, 
member 3 
1.521259 
 KIT  v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene homolog 
-1.20026 
 KLC3  kinesin light chain 3 -1.10721 
 KRT19  keratin 19 -4.20861 
 LBP  lipopolysaccharide binding protein -3.2013 
 LEMD2  LEM domain containing 2 -1.09221 
 LOC290704  similar to palladin -1.46407 
 LOC310926  hypothetical protein LOC310926 -3.70489 
 LOC498525  Bm403207 -1.51811 
 LSR  lipolysis stimulated lipoprotein 
receptor 
-2.15209 
 LTBP2  latent transforming growth factor 
beta binding protein 2 
-1.44674 
 LYPLA2  lysophospholipase II -1.13178 
 MAPK3  mitogen-activated protein kinase 3 -2.44177 
 MAPRE1  microtubule-associated protein, 
RP/EB family, member 1 
-1.51116 
99 
 
 MCART1  mitochondrial carrier triple repeat 1 -1.45733 
 MDK  midkine (neurite growth-promoting 
factor 2) 
-2.17035 
 MFGE8  milk fat globule-EGF factor 8 protein -2.24151 
 MMP12  matrix metallopeptidase 12 
(macrophage elastase) 
-1.8696 
 MSN  moesin -1.3974 
 MST1  macrophage stimulating 1 
(hepatocyte growth factor-like) 
1.531732 
 MUC4  mucin 4, cell surface associated -1.78116 
 MYH14  myosin, heavy chain 14, non-
muscle 
-1.68825 
 NCALD  neurocalcin delta -1.58757 
 NFIX  nuclear factor I/X (CCAAT-binding 
transcription factor) 
-1.71811 
 NID1  nidogen 1 -2.26977 
 NID2  nidogen 2 (osteonidogen) 1.154947 
 NISCH  nischarin -1.62492 
 NPM1 (includes 
EG:18148) 
 nucleophosmin 1 -1.51976 
 NPM1 (includes 
EG:4869) 
 nucleophosmin (nucleolar 
phosphoprotein B23, numatrin) 
-1.51976 
 NPR3  natriuretic peptide receptor 
C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) 
1.399811 
 NRTN  neurturin -1.24893 
 NS5ATP4  NS5A (hepatitis C virus) 
transactivated protein 4 
-1.48577 
 OBFC2A  oligonucleotide/oligosaccharide-
binding fold containing 2A 
1.527597 
 OLAH  oleoyl-ACP hydrolase -4.41303 
 PFN1  profilin 1 -1.2034 
 PIAS4  protein inhibitor of activated STAT, 
4 
-1.51279 
 PKP2  plakophilin 2 -1.927 
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 PLA2G2A  phospholipase A2, group IIA 
(platelets, synovial fluid) 
2.557423 
 PLAGL1  pleiomorphic adenoma gene-like 1 1.392866 
 PLSCR2  phospholipid scramblase 2 -1.81892 
 PLXNB2  plexin B2 -1.90056 
 PPIF  peptidylprolyl isomerase F -1.48118 
 PPP1CA  protein phosphatase 1, catalytic 
subunit, alpha isoform 
-1.59264 
 PRKAR2B  protein kinase, cAMP-dependent, 
regulatory, type II, beta 
1.334147 
 PROM1  prominin 1 -1.40398 
 PTMA (includes 
EG:29222) 
 prothymosin alpha -1.7989 
 PTMA (includes 
EG:5757) 
 prothymosin, alpha -1.7989 
 PTMS  parathymosin -1.81651 
 PXMP2  peroxisomal membrane protein 2, 
22kDa 
1.501408 
 QARS  glutaminyl-tRNA synthetase -1.53811 
 RAP1GAP 
(includes 
EG:5909) 
 RAP1 GTPase activating protein -1.6353 
 RELN  reelin -1.61663 
 RESP18  regulated endocrine-specific protein 
18 
1.215714 
 RNF10  ring finger protein 10 -1.19204 
 RPL18A  ribosomal protein L18a -1.54901 
 RPL30  ribosomal protein L30 4.012354 
 RPS2  ribosomal protein S2 -4.42427 
 RPS2 
PREDICTED 
 ribosomal protein S2, pseudogene 
6 
-4.42427 
 RPS7  ribosomal protein S7 -1.71474 
 SCNN1A  sodium channel, nonvoltage-gated 
1 alpha 
-1.22163 
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 SCNN1B  sodium channel, nonvoltage-gated 
1, beta 
-2.31668 
 SECTM1  secreted and transmembrane 1 -3.12136 
 SERPINA3  serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 3 
1.412449 
 SLC44A4  solute carrier family 44, member 4 -1.49615 
 SOD3  superoxide dismutase 3, 
extracellular 
1.131305 
 SOX10  SRY (sex determining region Y)-box 
10 
-1.9759 
 SPINT2  serine peptidase inhibitor, Kunitz 
type, 2 
-1.9472 
 ST6GALNAC2  ST6 (alpha-N-acetyl-neuraminyl-
2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-
sialyltransferase 2 
-2.14853 
 SUCNR1  succinate receptor 1 1.319822 
 TACR1  tachykinin receptor 1 -1.21528 
 TACSTD2  tumor-associated calcium signal 
transducer 2 
-1.62702 
 TAGLN2  transgelin 2 -3.72198 
 TGFB3  transforming growth factor, beta 3 -1.33287 
 TIMP2  TIMP metallopeptidase inhibitor 2 -2.78586 
 TMC4  transmembrane channel-like 4 -2.61694 
 TMEM158  transmembrane protein 158 -1.99916 
 TMEM184A  transmembrane protein 184A -1.77765 
 TOMM22  translocase of outer mitochondrial 
membrane 22 homolog (yeast) 
-1.47965 
 TOMM40  translocase of outer mitochondrial 
membrane 40 homolog (yeast) 
-1.13672 
 TSHR  thyroid stimulating hormone 
receptor 
1.742799 
 TSN  translin -2.1849 
 TSPAN4  tetraspanin 4 -1.30166 
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 UCP2  uncoupling protein 2 (mitochondrial, 
proton carrier) 
-1.71848 
 USP19  ubiquitin specific peptidase 19 -1.44886 
 VTN  vitronectin 1.391231 
 LYPLA2P1  lysophospholipase II pseudogene 1 -1.13178 
 MCART1L  mitochondrial carrier triple repeat 1-
like 
-1.45733 
 TOMM40B  translocase of outer mitochondrial 
membrane 40 homolog B (yeast) 
-1.13672 
 TOMM40L  translocase of outer mitochondrial 
membrane 40 homolog (yeast)-like 
-1.18674 
 BAT2D1  BAT2 domain containing 1 -1.34704 
 BAT2L  HLA-B associated transcript 2-like -1.26540 
 CD24B  CD24b antigen -3.39208 
 CD24C  CD24c antigen -2.67546 
 CD99L2  CD99 molecule-like 2 -2.04683 
 GPD1L  glycerol-3-phosphate 
dehydrogenase 1-like 
1.293394 
 Il18r  -2.00545 
 MST1R  macrophage stimulating 1 receptor 
(c-met-related tyrosine kinase) 
1.531732 
 LSR1  listeria resistance -2.15209 
 TSPAN2  tetraspanin 2 -1.30166 
 
CD14/TLR4/LY96 
 -1.44376 
 
JUN/JUNB/JUND 
 -1.35211 
 SMOC2  SPARC related modular calcium 
binding 2 
-1.47165 
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Table 2. List of genes differentially expressed 3 hours after exposure to 0.1 Gy of 80kVp X-
rays 
Symbol Entrez Gene Name Fold Change (log2) 
ACOT1 (includes 
EG:26897)  acyl-CoA thioesterase 1 
-1.28326 
 ACOT1 (includes 
EG:641371)  acyl-CoA thioesterase 1 
-1.28326 
 ALDOC  aldolase C, fructose-bisphosphate 
-2.35395 
 ANXA8 (includes 
EG:11752)  annexin A8 
-1.66973 
 ANXA8 (includes 
EG:653145)  annexin A8 
-1.66973 
 AOC3 
 amine oxidase, copper containing 3 (vascular 
adhesion protein 1) 
1.077522 
 AQP7  aquaporin 7 
1.331518 
 ARHGDIB  Rho GDP dissociation inhibitor (GDI) beta 
1.174741 
 CD53  CD53 molecule 
1.927602 
 CD74 
 CD74 molecule, major histocompatibility 
complex, class II invariant chain 
1.503892 
 CLCA2 (includes 
EG:362052)  chloride channel calcium activated 2 
-1.31796 
 CLCA2 (includes 
EG:80797)  chloride channel calcium activated 2 
-1.31796 
 CLCA2 (includes 
EG:9635)  chloride channel accessory 2 
-1.31796 
 CPA1  carboxypeptidase A1 (pancreatic) 
1.440268 
 CRB3  crumbs homolog 3 (Drosophila) 
-1.50732 
 CSN1S1 (includes 
EG:12990)  casein alpha s1 
-3.87554 
 CSN1S1 (includes 
EG:1446)  casein alpha s1 
-3.87554 
 CYP24A1 
 cytochrome P450, family 24, subfamily A, 
polypeptide 1 
-3.04088 
 DUOX1  dual oxidase 1 
-1.51006 
 DYNLT3  dynein, light chain, Tctex-type 3 
1.734937 
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 GJB2  gap junction protein, beta 2, 26kDa 
-2.16071 
 GRB7  growth factor receptor-bound protein 7 
-1.27412 
 HMGCS2 
 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 (mitochondrial) 
-1.75843 
 ICA1  islet cell autoantigen 1, 69kDa 
-1.27921 
 ITGA7  integrin, alpha 7 
1.340622 
 ITGB6  integrin, beta 6 
-1.43413 
 LPXN  leupaxin 
1.151434 
 LYPD3  LY6/PLAUR domain containing 3 
-1.62516 
 MIA  melanoma inhibitory activity 
-2.3021 
 MSLN  mesothelin 
-1.57986 
 MUC1  mucin 1, cell surface associated 
-1.04742 
 MUC4  mucin 4, cell surface associated 
-1.5575 
 NCALD  neurocalcin delta 
-1.30339 
 NPR3 
 natriuretic peptide receptor C/guanylate cyclase 
C (atrionatriuretic peptide receptor C) 
1.197441 
 OBFC2A 
 oligonucleotide/oligosaccharide-binding fold 
containing 2A 
1.782079 
 PLEK  pleckstrin 
1.593182 
 PPAP2C  phosphatidic acid phosphatase type 2C 
-1.49294 
 PRKCB  protein kinase C, beta 
1.701982 
 PTPN6 
 protein tyrosine phosphatase, non-receptor type 
6 
1.33895 
 PYGL  phosphorylase, glycogen, liver 
1.127892 
 RAP1GAP 
(includes EG:5909)  RAP1 GTPase activating protein 
-1.31293 
 RESP18  regulated endocrine-specific protein 18 
1.251276 
 S100B  S100 calcium binding protein B 
1.375019 
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 SCNN1A  sodium channel, nonvoltage-gated 1 alpha 
-1.14654 
 SERINC2  serine incorporator 2 
-1.31475 
 SERPINA12 
 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 12 
1.472555 
 SLC44A4  solute carrier family 44, member 4 
-1.2813 
 SOX10  SRY (sex determining region Y)-box 10 
-1.78786 
 ST6GALNAC2 
 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-
2,6-sialyltransferase 2 
-1.6303 
 TGFB3  transforming growth factor, beta 3 
-1.33962 
 TMEM184A  transmembrane protein 184A 
-1.34347 
 WAP  whey acidic protein 
-2.7355 
 ICA1L  islet cell autoantigen 1,69kDa-like 
-1.27921 
 PLEK2  pleckstrin 2 
-1.13757 
 SERPINA1 
 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 
1.472555 
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Table 3. List of genes differentially expressed 3 hours after exposure to 1 Gy of 80kVp X-
rays 
Symbol Entrez Gene Name Fold Change 
(log2) 
 ABCD2 
 ATP-binding cassette, sub-family D (ALD), member 
2 
1.291568 
 ACOT1 (includes 
EG:26897)  acyl-CoA thioesterase 1 
-1.48748 
 ACOT1 (includes 
EG:641371)  acyl-CoA thioesterase 1 
-1.48748 
 ACVR1C  activin A receptor, type IC 
1.762574 
 ADD3  adducin 3 (gamma) 
1.604066 
 ADIPOQ  adiponectin, C1Q and collagen domain containing 
1.41913 
 AGT 
 angiotensinogen (serpin peptidase inhibitor, clade 
A, member 8) 
1.241295 
 ANXA8 (includes 
EG:11752)  annexin A8 
-2.13406 
 ANXA8 (includes 
EG:653145)  annexin A8 
-2.13406 
 AOC3 
 amine oxidase, copper containing 3 (vascular 
adhesion protein 1) 
1.167846 
 AQP11  aquaporin 11 
1.15638 
 AQP7  aquaporin 7 
1.608711 
 AREG  amphiregulin 
-1.62227 
 ASAM  adipocyte-specific adhesion molecule 
1.456262 
 ASRGL1  asparaginase like 1 
1.473672 
 BCL2L14  BCL2-like 14 (apoptosis facilitator) 
-2.34847 
 BZW2  basic leucine zipper and W2 domains 2 
-1.46222 
 CA5B  carbonic anhydrase VB, mitochondrial 
1.346396 
 CACNB3  calcium channel, voltage-dependent, beta 3 subunit 
-1.53745 
 CCL21  chemokine (C-C motif) ligand 21 
-1.60737 
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 CCL7  chemokine (C-C motif) ligand 7 
2.064533 
 CCR1  chemokine (C-C motif) receptor 1 
1.233851 
 CD24  CD24 molecule 
-3.47291 
 CDH1  cadherin 1, type 1, E-cadherin (epithelial) 
-1.71472 
 CES1 (includes 
EG:1066) 
 carboxylesterase 1 (monocyte/macrophage serine 
esterase 1) 
2.016765 
 CES2 (includes 
EG:234671)  carboxylesterase 2 
1.189263 
 CES2 (includes 
EG:8824)  carboxylesterase 2 (intestine, liver) 
1.189263 
 CES3  carboxylesterase 3 
1.277086 
 CFB  complement factor B 
-1.14669 
 CFI  complement factor I 
-2.38297 
 CGREF1  cell growth regulator with EF-hand domain 1 
1.997955 
 CHDH  choline dehydrogenase 
-1.14864 
 CHST1 
 carbohydrate (keratan sulfate Gal-6) 
sulfotransferase 1 
-1.3066 
 CITED1 
 Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 1 
-2.38727 
 CLCA2 (includes 
EG:362052)  chloride channel calcium activated 2 
-1.68055 
 CLCA2 (includes 
EG:80797)  chloride channel calcium activated 2 
-1.68055 
 CLCA2 (includes 
EG:9635)  chloride channel accessory 2 
-1.68055 
 CLDN3  claudin 3 
-3.1061 
 CLDN4  claudin 4 
-1.8386 
 CLDN8  claudin 8 
-1.2458 
 CLU  clusterin 
1.07743 
 CMTM8 
 CKLF-like MARVEL transmembrane domain 
containing 8 
-2.24685 
 COL15A1  collagen, type XV, alpha 1 
1.343638 
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 COL1A1  collagen, type I, alpha 1 
1.142441 
 CPA1  carboxypeptidase A1 (pancreatic) 
1.942779 
 CPZ  carboxypeptidase Z 
1.475224 
 CRB3  crumbs homolog 3 (Drosophila) 
-1.96205 
 CSAD  cysteine sulfinic acid decarboxylase 
1.042063 
 CSF1  colony stimulating factor 1 (macrophage) 
1.443845 
 CSN1S1 (includes 
EG:12990)  casein alpha s1 
-4.60327 
 CSN1S1 (includes 
EG:1446)  casein alpha s1 
-4.60327 
 CSN1S2B 
(includes 
EG:12992)  casein alpha s2-like B 
-3.51592 
 CSN1S2B 
(includes 
EG:317712)  casein alpha s2-like B 
-3.51592 
 CSPG4  chondroitin sulfate proteoglycan 4 
1.680827 
 CX3CL1  chemokine (C-X3-C motif) ligand 1 
-1.3985 
 CYP11A1 
 cytochrome P450, family 11, subfamily A, 
polypeptide 1 
1.443982 
 CYP24A1 
 cytochrome P450, family 24, subfamily A, 
polypeptide 1 
-2.54179 
 DGAT2  diacylglycerol O-acyltransferase homolog 2 (mouse) 
1.676773 
 DLGAP4 
 discs, large (Drosophila) homolog-associated 
protein 4 
1.422329 
 DPYSL3  dihydropyrimidinase-like 3 
1.464703 
 DUOX1  dual oxidase 1 
-1.35902 
 DYNLT3  dynein, light chain, Tctex-type 3 
1.582418 
 EMP3  epithelial membrane protein 3 
1.11399 
 EZR  ezrin 
-2.0603 
 FGF7 
 fibroblast growth factor 7 (keratinocyte growth 
factor) 
1.359386 
 FGG  fibrinogen gamma chain 
-1.86742 
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 FXYD3  FXYD domain containing ion transport regulator 3 
-2.54401 
 GALNT3 
 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 3 (GalNAc-T3) 
-2.2771 
 GATA3  GATA binding protein 3 
-2.29378 
 GJB2  gap junction protein, beta 2, 26kDa 
-2.49704 
 GRB7  growth factor receptor-bound protein 7 
-1.51715 
 HMGCS2 
 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 
(mitochondrial) 
-2.50989 
 IGFBP2  insulin-like growth factor binding protein 2, 36kDa 
-2.85254 
 IL18  interleukin 18 (interferon-gamma-inducing factor) 
-1.73363 
 IL1R2  interleukin 1 receptor, type II 
1.422606 
 IRX2  iroquois homeobox 2 
-2.24454 
 ITGA1  integrin, alpha 1 
1.556625 
 ITGA7  integrin, alpha 7 
1.269478 
 ITGB6  integrin, beta 6 
-1.49668 
 KCNB1 
 potassium voltage-gated channel, Shab-related 
subfamily, member 1 
1.59028 
 KCNK1  potassium channel, subfamily K, member 1 
-2.68838 
 KLC3  kinesin light chain 3 
-1.0499 
 KRT14  keratin 14 
-2.86507 
 KRT15  keratin 15 
-2.93569 
 KRT17  keratin 17 
-1.18915 
 KRT19  keratin 19 
-3.75348 
 KRT8  keratin 8 
-2.9519 
 LBP  lipopolysaccharide binding protein 
-2.26107 
 LGALS7  lectin, galactoside-binding, soluble, 7 
-1.45534 
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 LSAMP  limbic system-associated membrane protein 
1.679468 
 LSR  lipolysis stimulated lipoprotein receptor 
-2.28006 
 LTBP2 
 latent transforming growth factor beta binding 
protein 2 
-1.54146 
 LYPD3  LY6/PLAUR domain containing 3 
-2.14915 
 MDK  midkine (neurite growth-promoting factor 2) 
-1.87434 
 MFGE8  milk fat globule-EGF factor 8 protein 
-1.52772 
 MGLL  monoglyceride lipase 
2.326522 
 MGMT  O-6-methylguanine-DNA methyltransferase 
1.05849 
 MIA  melanoma inhibitory activity 
-3.21813 
 MLPH  melanophilin 
-1.1281 
 MMP12  matrix metallopeptidase 12 (macrophage elastase) 
-1.70063 
 MMP23B  matrix metallopeptidase 23B 
1.35272 
 MSLN  mesothelin 
-1.6473 
 MT1A  metallothionein 1A 
-1.88259 
 MUC1  mucin 1, cell surface associated 
-1.10772 
 MUC4  mucin 4, cell surface associated 
-1.76392 
 MYH14  myosin, heavy chain 14, non-muscle 
-1.65216 
 NCALD  neurocalcin delta 
-1.793 
 NPR3 
 natriuretic peptide receptor C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) 
1.227653 
 NRTN  neurturin 
-1.22351 
 NUP210  nucleoporin 210kDa 
-1.31999 
 OBFC2A 
 oligonucleotide/oligosaccharide-binding fold 
containing 2A 
1.590383 
 OLAH  oleoyl-ACP hydrolase 
-3.54133 
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 PALMD  palmdelphin 
1.283961 
 PC  pyruvate carboxylase 
1.526366 
 PCOLCE  procollagen C-endopeptidase enhancer 
1.279318 
 PCP4  Purkinje cell protein 4 
-2.21855 
 PENK  proenkephalin 
-1.73748 
 PKP2  plakophilin 2 
-2.03685 
 PLA2G2A 
 phospholipase A2, group IIA (platelets, synovial 
fluid) 
1.950802 
 PLIN2  perilipin 2 
1.128144 
 PLSCR2  phospholipid scramblase 2 
-1.80613 
 PMM1  phosphomannomutase 1 
1.264668 
 PPAP2C  phosphatidic acid phosphatase type 2C 
-1.70115 
 PPIF  peptidylprolyl isomerase F 
-1.87262 
 PPP1CB 
 protein phosphatase 1, catalytic subunit, beta 
isoform 
-1.15238 
 PPP1R1B 
 protein phosphatase 1, regulatory (inhibitor) subunit 
1B 
-1.04281 
 PRKAR2B 
 protein kinase, cAMP-dependent, regulatory, type II, 
beta 
1.099812 
 PROM1  prominin 1 
-1.87177 
 PRRX1  paired related homeobox 1 
2.093468 
 PYGL  phosphorylase, glycogen, liver 
1.234931 
 RAP1GAP 
(includes EG:5909)  RAP1 GTPase activating protein 
-1.55694 
 RELN  reelin 
-1.65086 
 RESP18  regulated endocrine-specific protein 18 
1.480874 
 RGS7  regulator of G-protein signaling 7 
1.525065 
 RHBG  Rh family, B glycoprotein (gene/pseudogene) 
1.562568 
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 RPL30  ribosomal protein L30 
3.235673 
 S100B  S100 calcium binding protein B 
1.88612 
 SAT1  spermidine/spermine N1-acetyltransferase 1 
-1.09281 
 SCD  stearoyl-CoA desaturase (delta-9-desaturase) 
1.054327 
 SCNN1A  sodium channel, nonvoltage-gated 1 alpha 
-1.29534 
 SCNN1B  sodium channel, nonvoltage-gated 1, beta 
-2.26947 
 SDPR  serum deprivation response 
1.584154 
 SECTM1  secreted and transmembrane 1 
-2.771 
 SERINC2  serine incorporator 2 
-1.38035 
 SERPINA12 
 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 12 
1.842721 
 SHOX2  short stature homeobox 2 
1.162329 
 SLC22A3 
 solute carrier family 22 (extraneuronal monoamine 
transporter), member 3 
1.481995 
 SLC44A4  solute carrier family 44, member 4 
-1.4608 
 SLC7A10 
 solute carrier family 7, (neutral amino acid 
transporter, y+ system) member 10 
1.794097 
 SOX10  SRY (sex determining region Y)-box 10 
-1.98022 
 SPINT1  serine peptidase inhibitor, Kunitz type 1 
-1.11954 
 SPINT2  serine peptidase inhibitor, Kunitz type, 2 
-1.98792 
 ST6GALNAC2 
 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 2 
-1.90031 
 SV2B  synaptic vesicle glycoprotein 2B 
2.307462 
 TACSTD2  tumor-associated calcium signal transducer 2 
-1.74162 
 TC2N  tandem C2 domains, nuclear 
-1.48321 
 TEX264  testis expressed 264 
1.280726 
 TGFB3  transforming growth factor, beta 3 
-1.30275 
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 TMC4  transmembrane channel-like 4 
-2.56555 
 TMEM184A  transmembrane protein 184A 
-1.67004 
 TSHR  thyroid stimulating hormone receptor 
1.390339 
 UCP2  uncoupling protein 2 (mitochondrial, proton carrier) 
-1.33222 
 WAP  whey acidic protein 
-2.81514 
 WDFY1  WD repeat and FYVE domain containing 1 
2.068261 
 WFDC2  WAP four-disulfide core domain 2 
-2.0347 
 NUP210L  nucleoporin 210kDa-like 
-1.31999 
 PCOLCE2 
(includes 
EG:26577)  procollagen C-endopeptidase enhancer 2 
1.279318 
 PCOLCE2 
(includes 
EG:684050)  procollagen C-endopeptidase enhancer 2 
1.279318 
 MMP23A  matrix metallopeptidase 23A (pseudogene) 
1.35272 
 CCR1L1  chemokine (C-C motif) receptor 1-like 1 
1.233851 
 CSF1R  colony stimulating factor 1 receptor 
1.443845 
 Il18r 
 
-1.73363 
 SMOC2  SPARC related modular calcium binding 2 
-2.64634 
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Table 4. List of genes differentially expressed 2 weeks after exposure to 0.1 Gy of 30kVp X-
rays 
Symbol Entrez Gene Name Fold Change (log2) 
 ELN  elastin 
-1.5452 
 ITGB1 
 integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
-1.05207 
 NNAT  neuronatin 
-1.08815 
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Table 5. List of genes differentially expressed 2 weeks after exposure to 0.1 Gy of 80kVp X-
rays 
Symbol Entrez Gene Name Fold Change (log2) 
 ACE 
 angiotensin I converting 
enzyme (peptidyl-dipeptidase A) 
1 
-2.24477 
 FAP 
 fibroblast activation protein, 
alpha 
-1.31783 
 Fcgr3 
 
-1.0876 
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Table 6. List of genes differentially expressed 2 weeks after exposure to 1 Gy of 80kVp X-
rays 
Symbol Entrez Gene Name Fold Change 
(log2) 
 HSP90AA1 
 heat shock protein 90kDa alpha (cytosolic), 
class A member 1 
1.230511 
 COL5A1  collagen, type V, alpha 1 
-1.12193 
 ACE 
 angiotensin I converting enzyme (peptidyl-
dipeptidase A) 1 
-2.15796 
 CSF1R  colony stimulating factor 1 receptor 
-1.4715 
 WNT2B 
 wingless-type MMTV integration site family, 
member 2B 
-1.42072 
 DNM1L  dynamin 1-like 
-1.34629 
 LAMB2L  laminin, beta 2-like 
-1.28102 
 PCOLCE2 
(includes 
EG:684050)  procollagen C-endopeptidase enhancer 2 
-1.32221 
 PCOLCE2 
(includes 
EG:26577)  procollagen C-endopeptidase enhancer 2 
-1.32221 
 WNT2 
 wingless-type MMTV integration site family 
member 2 
-1.42072 
 THBD  thrombomodulin 
-1.56622 
 RAMP2 
 receptor (G protein-coupled) activity modifying 
protein 2 
-1.18181 
 QPRT  quinolinate phosphoribosyltransferase 
-1.26425 
 PTGIS  prostaglandin I2 (prostacyclin) synthase 
-1.53013 
 PROCR  protein C receptor, endothelial (EPCR) 
-1.6477 
 PPAP2B  phosphatidic acid phosphatase type 2B 
-1.11399 
 PLAT  plasminogen activator, tissue 
-1.24503 
 PDPN  podoplanin 
-1.23253 
 PCOLCE  procollagen C-endopeptidase enhancer 
-1.32221 
 NUCB2  nucleobindin 2 
-1.32061 
 NT5E  5'-nucleotidase, ecto (CD73) 
-1.40654 
 NOVA1  neuro-oncological ventral antigen 1 
-1.41956 
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 NBL1  neuroblastoma, suppression of tumorigenicity 1 
-1.57246 
 METRNL  meteorin, glial cell differentiation regulator-like 
-1.30896 
 LTBP1 
 latent transforming growth factor beta binding 
protein 1 
-1.24871 
 LRRC17  leucine rich repeat containing 17 
-1.7696 
 LOXL1  lysyl oxidase-like 1 
-1.265 
 LOC310926  hypothetical protein LOC310926 
1.973774 
 LOC305633  similar to Antxr2 protein 
-1.14967 
 LAMB2  laminin, beta 2 (laminin S) 
-1.28102 
 KLF4  Kruppel-like factor 4 (gut) 
-1.12312 
 ITGBL1 
 integrin, beta-like 1 (with EGF-like repeat 
domains) 
-1.27348 
 GSTM2  glutathione S-transferase mu 2 (muscle) 
-1.41369 
 GAS7  growth arrest-specific 7 
-1.66603 
 GAP43  growth associated protein 43 
-2.26783 
 Fcgr3 
 
-1.08019 
 FEZ1 
 fasciculation and elongation protein zeta 1 
(zygin I) 
-1.65734 
 FBN1  fibrillin 1 
-1.38892 
 FAP  fibroblast activation protein, alpha 
-1.38291 
 ENTPD2 
 ectonucleoside triphosphate 
diphosphohydrolase 2 
-1.18712 
 ELN  elastin 
-1.98489 
 ECM1  extracellular matrix protein 1 
-1.83312 
 DNM1  dynamin 1 
-1.34629 
 CSF1  colony stimulating factor 1 (macrophage) 
-1.4715 
 C1QC 
 complement component 1, q subcomponent, C 
chain 
-1.26776 
 C1QA 
 complement component 1, q subcomponent, A 
chain 
-1.19117 
 BMP7  bone morphogenetic protein 7 
-1.45355 
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 ANPEP  alanyl (membrane) aminopeptidase 
-1.55912 
 ADCY2  adenylate cyclase 2 (brain) 
-2.09126 
 
 
 
Table 7. List of selected genes that were similarly regulated by all exposure types. 
    Fold change 
Target ID Gene name 0.1(30) 0.1(80) 1.0(80) 
ALDOC  aldolase C, fructose-bisphosphate -2.8 -2.4 -3.0 
ANXA8  annexin A8 -2.3 -1.7 -2.1 
AOC3 
 amine oxidase, copper containing 3 (vascular 
adhesion protein 1) 1.2 1.1 1.2 
ASRGL1  asparaginase like 1 1.4 1.1 1.5 
BCL2L14  BCL2-like 14 (apoptosis facilitator) -2.3 -1.6 -2.3 
CDH1  cadherin 1, type 1, E-cadherin (epithelial) -1.9 -1.3 -1.7 
CGREF1  cell growth regulator with EF-hand domain 1 1.6 1.2 2.0 
CLCA2  chloride channel calcium activated 2 -1.8 -1.3 -1.7 
CLDN4  claudin 4 -1.9 -1.4 -1.8 
CPA1  carboxypeptidase A1 (pancreatic) 1.5 1.4 1.9 
CRB3  crumbs homolog 3 (Drosophila) -1.8 -1.5 -2.0 
CREB3L4 
 cAMP responsive element binding protein 3-like 
4 -1.6 -1.1 -1.6 
CSPG4  chondroitin sulfate proteoglycan 4 1.7 1.2 1.7 
CYP24A1 
 cytochrome P450, family 24, subfamily A, 
polypeptide 1 -3.4 -3.0 -2.5 
DUOX1  dual oxidase 1 -1.3 -1.5 -1.4 
GRB7  growth factor receptor-bound protein 7 -1.4 -1.3 -1.5 
HMGCS2 
 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 (mitochondrial) -1.8 -1.8 -2.5 
ICA1  islet cell autoantigen 1, 69kDa -1.2 -1.3 -1.2 
IL1R2  interleukin 1 receptor, type II 1.6 1.2 1.4 
ITGA7  integrin, alpha 7 2.0 1.3 1.3 
LYPD3  LY6/PLAUR domain containing 3 -1.8 -1.6 -2.1 
MIA1  melanoma inhibitory activity -2.8 -2.3 -3.2 
MUC4  mucin 4, cell surface associated -1.8 -1.6 -1.8 
MYH14  myosin, heavy chain 14, non-muscle -1.7 -1.3 -1.7 
NCALD  neurocalcin delta -1.6 -1.3 -1.8 
NPR3 
 natriuretic peptide receptor C/guanylate cyclase 
C (atrionatriuretic peptide receptor C) 1.4 1.2 1.2 
NRTN  neurturin -1.2 -1.1 -1.2 
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OBFC2A 
 oligonucleotide/oligosaccharide-binding fold 
containing 2A 1.5 1.8 1.6 
PCOLCE  procollagen C-endopeptidase enhancer 1.2 1.0 1.3 
PKP2  plakophilin 2 -1.9 -1.4 -2.0 
PPAP2C  phosphatidic acid phosphatase type 2C -2.0 -1.5 -1.7 
RAMP1 
 receptor (G protein-coupled) activity modifying 
protein 1 1.4 1.1 1.2 
RAP1GA1  RAP1 GTPase activating protein -1.6 -1.3 -1.6 
RESP18  regulated endocrine-specific protein 18 1.2 1.3 1.5 
RTKN  rhotekin -1.1 -1.3 -1.3 
SCNN1A  sodium channel, nonvoltage-gated 1 alpha -1.2 -1.1 -1.3 
SLC44A4  solute carrier family 44, member 4 -1.5 -1.3 -1.5 
SOX10  SRY (sex determining region Y)-box 10 -2.0 -1.8 -2.0 
ST6GALNAC2 
 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-
2,6-sialyltransferase 2 -2.1 -1.6  -1.3 
TCFAP2C 
 transcription factor AP-2 gamma (activating 
enhancer binding protein 2 gamma) -2.2 -1.4 -2.0 
TGFB3  transforming growth factor, beta 3 -1.3 -1.3 -1.3 
TMEM184A  transmembrane protein 184A -1.8 -1.3 -1.7 
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